Introduction {#s1}
============

Defects in pancreatic endocrine cell development confer increased diabetes risk later in life ([@bib7]). Therefore, a detailed understanding of the factors that orchestrate endocrine cell differentiation is highly relevant to human disease. Many of the molecular mechanisms that underlie the formation of pancreatic endocrine cells have been defined ([@bib46]; [@bib49]). However, despite some evidence that long noncoding RNAs (lncRNAs) are important for proper development and function of pancreatic beta cells ([@bib4]; [@bib34]; [@bib62]), a systematic functional assessment of the noncoding transcriptome during pancreas development is lacking.

Most lncRNAs with to date demonstrated roles in the regulation of fundamental developmental processes are active in the cell\'s nucleus ([@bib14]; [@bib19]; [@bib21]; [@bib22]; [@bib27]; [@bib29]; [@bib41]). However, a large proportion of lncRNAs is predominantly cytosolic ([@bib9]; [@bib58]), and the functional relevance of these lncRNAs has remained unexplored in the context of human development. It is now widely accepted that many cytosolic lncRNAs possess short, 'non-canonical' open reading frames (sORFs) that are translated ([@bib8]; [@bib30]; [@bib47]). What fraction of these non-canonical ORFs is functional, and whether sORF translation serves a pure regulatory purpose or results in the production of stable microproteins, remains an active topic of debate ([@bib24]; [@bib48]). Since high rates of conservation have historically been employed for the identification and annotation of canonical protein coding sequences ([@bib26]; [@bib35]), a primary reason for doubting the protein-coding capacity of sORFs in presumed lncRNAs is their generally poor sequence conservation across species. To address these questions, several recent studies have systematically assessed the biological activity of newly discovered sORFs, revealing that many produce evolutionary young microproteins with roles across cellular organelles and processes, and a subset being essential for cell survival ([@bib12]; [@bib32]; [@bib38]; [@bib59]). This previously unrecognized coding capacity of supposedly noncoding RNAs illustrates their functional diversity and has called into question the noncoding classification of some lncRNAs. Thus, there is a need for careful investigation and dissection of any gene\'s coding and noncoding functions.

LncRNAs, translated or fully noncoding, are not randomly distributed in the genome but are frequently located close to, and coregulated with, canonical protein-coding genes in cis ([@bib29]; [@bib36]; [@bib59]). For example, the lncRNAs *DIGIT* (also known as *GSC-DT*) and *Gata6as* (also known as *lncGata6* or *GATA6-AS1*) have been reported to enhance expression of divergently expressed endoderm regulators *Goosecoid* (*GSC*) and *Gata6*, respectively ([@bib14]; [@bib29]; [@bib36]). Similarly, the *Pax6*-associated lncRNA *Paupar* promotes pancreatic islet alpha cell formation through the alternative splicing of *Pax6* transcripts in mice ([@bib51]). Furthermore, *LINC00261* (also known as *DEANR1)* and its neighboring TF *FOXA2* are both induced in endoderm formation, during which *LINC00261* has been proposed to positively regulate *FOXA2* expression ([@bib19]). However, whether such *cis*-acting lncRNAs are translated and may exert cytosolic functions through *trans*-acting, microprotein-dependent mechanisms relevant for endoderm and pancreas development is not known.

In this study, we classified lncRNAs based on their dynamic regulation, subcellular localization, and translation in a hESC differentiation system that recapitulates in vivo pancreas development. Next, we used this classification to prioritize select dynamically regulated and highly translated lncRNAs for deletion in hESCs, followed by extensive phenotypic characterization across multiple intermediate states of pancreas development. Nine out of the ten selected lncRNAs were not essential for pancreatic development and, despite their vicinity to lineage-determining TFs, none of these lncRNAs regulated the expression of these TFs in cis.

The deletion of one lncRNA, *LINC00261*, impaired human endocrine cell development and led to a significant reduction in the number of insulin-producing cells. Contrary to previous studies of *LINC00261* knockdown hESCs ([@bib19]), deletion of *LINC00261* had no effect on the expression of nearby TF *FOXA2* or other proximal genes, suggesting control of endocrine cell formation through a *trans-* rather than *cis*-regulatory mechanism. *LINC00261* was among the most highly translated lncRNAs based on ribosome profiling (Ribo-seq) and produced multiple microproteins with distinct subcellular localizations upon overexpression in vitro. To systematically assess *LINC00261*\'s coding and noncoding functions, we separately introduced frameshift mutations into each of seven identified *LINC00261* sORFs. However, rigorous phenotypic characterization revealed no apparent consequences of loss of each of the seven *LINC00261*-sORF-encoded microproteins on endocrine cell development. Our comprehensive assessment of functional lncRNA translation identified a likely *trans*-regulatory role for *LINC00261* in endocrine cell differentiation that appears to be independent of the seven microproteins that were individually deleted. With this detailed investigation we provide a blueprint for the proper dissection of a gene\'s coding and noncoding roles in a human disease-relevant system.

Results {#s2}
=======

LncRNAs and nearby lineage-determining transcription factors exhibit dynamic coregulation during pancreas development {#s2-1}
---------------------------------------------------------------------------------------------------------------------

To identify lncRNAs involved in the regulation of pancreas development, we profiled RNA expression at five defined stages of hESC differentiation toward the pancreatic lineage: hESCs (ES), definitive endoderm (DE), primitive gut tube (GT), early pancreatic progenitor (PP1), and late pancreatic progenitor (PP2) ([Figure 1A](#fig1){ref-type="fig"}). While some lncRNAs were constitutively expressed (n = 592; 25.3%), the majority showed dynamic expression patterns (n = 1745; 74.7%), being either strongly enriched in (n = 874; 37.4%) or specific to (n = 871; 37.3%) a single developmental intermediate of pancreatic lineage progression ([Figure 1B](#fig1){ref-type="fig"} and [Figure 1---source data 1A](#fig1sdata1){ref-type="supplementary-material"}). The expression of many of these dynamically regulated lncRNAs correlated with that of proximal coding genes ([Figure 1---figure supplement 1A--D](#fig1s1){ref-type="fig"} and [Figure 1---source data 1B,C](#fig1sdata1){ref-type="supplementary-material"}), further exemplified by a subset of lncRNAs that was specifically coregulated with the key endodermal and pancreatic TFs *GATA6, FOXA2*, *PDX1,* and *SOX9* ([Figure 1C,D](#fig1){ref-type="fig"}). The expression coregulation of these lncRNA-TF pairs is likely explained by a shared chromatin environment ([Figure 1---figure supplement 1E--H](#fig1s1){ref-type="fig"}), which raises the possibility that like the TFs, the function of the lncRNAs is also required for endoderm and pancreas development.

![LncRNA expression and regulation during pancreatic differentiation.\
(**A**) Stages of directed differentiation from human embryonic stem cell (hESCs) to hormone-producing endocrine cells. The color scheme for each stage is used across all figures. (**B**) K-means clustering of all lncRNAs expressed (RPKM ≥ 1) during pancreatic differentiation based on their expression z-score (mean of n = 2 independent differentiations per stage; from CyT49 hESCs). (**C,D**) Left: Scatterplots comparing the expression of early (**C**) and late (**D**) expressed endodermal transcription factors (TFs) with the expression of their neighboring lncRNAs across 38 tissues. The dot color indicates the germ layer of origin of these tissues. Pearson correlation coefficients and p-values (t-test) are displayed. Right: Distribution of the Pearson correlation coefficients for each TF with all Ensembl 87 genes across the same 38 tissues. Dashed lines denote the correlation for the neighboring lncRNA, which for all lncRNAs shown is higher than expected by chance. See also [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.\
Figure 1---source data 1.Identification, regulation, and characterization of lncRNAs during pancreatic differentiation.(**A**) Gene expression during pancreatic differentiation (RPKM). (**B**) lncRNA-proximal TFs, by cluster in correlation heatmap ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). (**C**) GO enrichment and KEGG pathway analysis for each cluster in the correlation heatmap ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}).](elife-58659-fig1){#fig1}

Many pancreatic progenitor-expressed lncRNAs are cytoplasmically enriched and translated {#s2-2}
----------------------------------------------------------------------------------------

Although most functional roles described for lncRNAs to date have been predominantly nuclear ([@bib31]), multiple recent studies have shown that many lncRNAs are cytosolic and translated into sometimes biologically active microproteins (reviewed in [@bib30]). To further characterize the above-identified dynamically regulated lncRNAs, we analyzed their subcellular localization and translation potential using fractionation RNA-seq and Ribo-seq across multiple hESC clones independently differentiated into PP2 stage pancreatic progenitors ([Figure 2A](#fig2){ref-type="fig"}). Of all lncRNAs expressed in two replicate differentiations into PP2 cells, we classified 21% (n = 347) as localized to the nucleus, whereas a larger number (n = 563; 34%) primarily resided in the cytosol ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"} and [Figure 2---source data 1A](#fig2sdata1){ref-type="supplementary-material"}). This subcellular distribution of pancreatic lncRNAs is in agreement with previous lncRNA localization studies by us and others ([@bib9]; [@bib13]; [@bib53]; [@bib58]). LncRNAs enriched in the cytosol were expressed at higher levels than nucleus-localized lncRNAs, with expression levels similar to canonical protein-coding mRNAs ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Intriguingly, almost half (49.4%) of all cytosol-enriched lncRNAs (278 out of 563) displayed dynamic expression regulation during the differentiation of hESCs to pancreatic progenitors, raising the possibility that many lncRNAs with putative developmental functions do not act in the nucleus, but instead in the cytosol where they may be translated.

![Cytosolic lncRNAs contain translated small open reading frames.\
(**A**) Overview of experimental strategy for subcellular fractionation and Ribo-seq-based identification of translated small open reading frames (sORFs) from lncRNAs expressed in PP2 cells. Replicates from six independent differentiations to PP2 stage each for total (polyA) RNA-seq and Ribo-seq experiments, and two biological replicates for the subcellular fractionation were analyzed. The histogram on the far right depicts the size distribution of the sORF-encoded small peptides as number of amino acids (aa). The pie chart summarizes the percentages of constitutively and dynamically expressed sORF-encoding lncRNAs during pancreatic differentiation of CyT49 hESCs. (**B--E**) Left: Bar graphs showing nuclear and cytosolic expression (in RPKM) of lncRNAs *RP11-834C11.4* (**B**), *LINC00261* (**C**), *MIR7-3HG* (**D**), and *LHFPL3-AS2* (**E**). Data are shown as mean, with individual data points represented by dots (n = 2 biological replicates). Right: Subcellular fractionation RNA-seq, Ribo-seq, and P-site tracks (ribosomal P-sites inferred from ribosome footprints on ribosome-protected RNA) for loci of the depicted lncRNAs. Identified highest stringency sORFs (ORF in 6/6 replicates) are shown in red. For *LINC00261*, visually identified sORFs 1 and 2 are also shown. Heatmaps in the top right visualize the relative expression of the shown lncRNAs during pancreatic differentiation (means of two biological replicates per stage), on a minimum (white)/maximum (dark blue) scale. (**F**) In vivo translation reporter assays testing whether sORFs computationally defined in (**A**) give rise to translation products in HEK293T cells when fused in-frame to a GFP reporter. Left: Schematic of the constructs (gray: *PGK* promoter, black: lncRNA sequence 5' to sORF to be tested, red: sORF, green: GFP ORF). Right: Representative DIC and GFP images of HEK293T cells transiently transfected with the indicated reporter constructs. Scale bars = 50 µm. See also [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} and [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}.\
Figure 2---source data 1.RNA-seq after subcellular fractionation and Ribo-seq in PP2 cells.(**A**) Subcellular fractionation of PP2 stage cells (RPKM). (**B**) Ribo-seq/mRNA-seq contaminant filtering statistics, read size distribution, and Pearson correlation coefficients of all sequenced Ribo-seq and polyA RNA-seq libraries. (**C**) All ORFs detected by RiboTaper, including lncRNA sORFs. (**D**) lncRNA sORFs detected by RiboTaper and conservation statistics (PhyloCSF scores). (**E**) Translational efficiency calculations.](elife-58659-fig2){#fig2}

To investigate the translation potential of these cytosolic lncRNAs, we used Ribo-seq, through which we obtained exceptionally deep and high quality translatome coverage across six replicate differentiations ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"} and [Figure 2---source data 1B](#fig2sdata1){ref-type="supplementary-material"}). As nearly 90% of the sequenced ribosomal footprints exhibited clear 3-nucleotide codon movement characteristic of translation ([Figure 2---figure supplement 1D--F](#fig2s1){ref-type="fig"}), these data have strong predictive value for the computational detection of non-canonical ORFs, such as upstream ORFs (uORFs) in the 5\' leader sequences of mRNAs and sORFs in genes annotated as lncRNAs ([Figure 2---source data 1C](#fig2sdata1){ref-type="supplementary-material"}). Requiring stringent reproducibility criteria (the exact ORF needed to be detected by RiboTaper ([@bib10]) in at least four out of six replicates), we identified a total of 625 new sORFs in lncRNAs with a median length of 47 amino acids (aa) ([Figure 2---source data 1D](#fig2sdata1){ref-type="supplementary-material"}). The majority of detected sORFs (76%; n = 477/625) is currently not present in the [sORFs.org](http://www.sorfs.org/) database ([@bib37]). The translated sORFs are located within 285 cytosolically localized lncRNAs (25.3% of all expressed lncRNAs) ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}), which are expressed at higher levels than untranslated lncRNAs ([Figure 2---figure supplement 1G](#fig2s1){ref-type="fig"}) and exhibit translational efficiencies similar to mRNAs ([Figure 2---figure supplement 1H](#fig2s1){ref-type="fig"} and [Figure 2---source data 1E](#fig2sdata1){ref-type="supplementary-material"}). Of note, almost none of the newly identified sORFs are highly conserved across species, as judged by their low PhyloCSF scores ([@bib26]; [Figure 2---source data 1D](#fig2sdata1){ref-type="supplementary-material"}).

Using approaches similar to ours, non-canonical sORFs have previously been characterized in multiple immortalized human cell lines ([@bib8]; [@bib10]; [@bib12]; [@bib18]; [@bib32]; [@bib38]; [@bib40]) and human tissues ([@bib59]). However, to our knowledge, our data constitute the first comprehensive set of non-canonical human ORFs generated from a non-transformed human cell model of development, providing a valuable resource for future functional studies.

Translated lncRNAs in pancreatic progenitors produce microproteins with distinct subcellular localizations {#s2-3}
----------------------------------------------------------------------------------------------------------

Having established that many stage-specific pancreatic lncRNAs are translated, we next sought to validate their translation potential through independent experimental approaches, additionally investigating the production of the predicted microproteins at the protein level. To this end, we first performed coupled in vitro transcription:translation assays on endogenous and complete transcript isoforms of four of the most highly translated lncRNAs (*LINC00261*, *RP11-834C11.4, LHFPL3-AS2*, and *MIR7-3HG*; [Figure 2---figure supplement 1I](#fig2s1){ref-type="fig"}; expression and ORF information in [Figure 2B--E](#fig2){ref-type="fig"}). Second, we generated a series of in vivo translation reporter constructs to assess the subcellular localization of microproteins translated from each of ten sORFs derived from the same four lncRNAs. Transient expression of individual constructs carrying in-frame GFP fusions in HEK293T cells produced GFP signal for all ten assayed microproteins, which was abolished upon introduction of a frameshift within the sORF or a stop codon following the sORF sequence ([Figure 2F](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1J--L](#fig2s1){ref-type="fig"}). To rule out a possible localization bias induced by the GFP fusion, we also expressed a FLAG-tag fusion peptide (*RP11-834C11.4* sORF-1xFLAG), which revealed a cytoplasmic localization identical to the one observed for the GFP construct ([Figure 2---figure supplement 1J](#fig2s1){ref-type="fig"}). While most sORF-GFP fusion products were ubiquitously distributed throughout transfected cells, *LINC00261* sORF4-GFP specifically localized to mitochondria ([Figure 2---figure supplement 1K](#fig2s1){ref-type="fig"}), and *LINC00261* sORF7-GFP exhibited a perinuclear accumulation pattern reminiscent of aggresomes ([Figure 2---figure supplement 1L](#fig2s1){ref-type="fig"}). Taken together, our results validate the translation potential of sORFs encoded by pancreatic progenitor-expressed lncRNAs and show that, upon ectopic expression, these translation events result in the production of microproteins with different subcellular localizations.

Deletion phenotypes of translated lncRNAs during hESC pancreatic differentiation {#s2-4}
--------------------------------------------------------------------------------

To identify potential functional roles of translated lncRNAs during pancreas development, we selected ten candidates for CRISPR/Cas9-based genome editing in hESCs through excision of the lncRNA promoter or entire lncRNA locus ([Figure 3A,B](#fig3){ref-type="fig"}). These ten lncRNAs were prioritized based on (i) high expression and endodermal tissue-specificity, (ii) dynamic regulation during pancreas development, (iii) abundant translation of sORFs, and (iv) proximity to TFs with known roles in endoderm and pancreas development. For seven of the selected lncRNAs, translation was highly abundant and reproducibly detected across Ribo-seq replicates: *LINC00617* (also known as *TUNAR;* [@bib27]), *GATA6-AS1* (also known as *GATA6-AS;* [@bib36]), *LINC00261*, *RP11-834C11.4*, *SOX9-AS1*, *MIR7-3HG,* and *LHFPL3-AS2*. Although for two additional lncRNAs the translation potential could not be determined, they were nonetheless included because of a previously reported requirement for definitive endoderm formation (*DIGIT*, also known as *GSC-DT*) ([@bib14]) and genomic localization adjacent to the definitive endoderm TF *LHX1* (*RP11-445F12.1*, also known as *LHX1-DT*). Lastly, *LINC00479* was chosen as a non-translated control with expression dynamics and a subcellular localization similar to *LINC00261*. Of note, for each of the ten selected lncRNAs, we generated at least two independent hESC knockout (KO) clones and used different combinations of single guide RNAs where possible ([Figure 3---source data 1A](#fig3sdata1){ref-type="supplementary-material"}).

![A small-scale CRISPR loss-of-function screen for dynamically expressed and translated lncRNAs during pancreatic differentiation.\
(**A**) qRT-PCR analysis of candidate lncRNAs during pancreatic differentiation of H1 hESCs relative to the ES stage. Data are shown as mean ± S.E.M. (mean of n = 2--6 independent differentiations per stage; from H1 hESCs). Individual data points are represented by dots. See also [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}. (**B**) CRISPR-based lncRNA knockout (KO) strategy in H1 hESCs and subsequent phenotypic characterization. (**C**) Immunofluorescence staining for OCT4 and SOX17 in DE from control (ctrl) and KO cells for the indicated lncRNAs (representative images, n ≥ 3 independent differentiations; at least two KO clones were analyzed). (**D**) qRT-PCR analysis of DE lineage markers in DE from control and lncRNA KO (-/-) cells. TF genes in cis to the lncRNA locus are highlighted in red. Data are shown as mean ± S.E.M. (n = 3--16 replicates from independent differentiations and different KO clones). Individual data points are represented by dots. NS, p-value\>0.05; t-test. See also [Figure 3---source data 3](#fig3sdata3){ref-type="supplementary-material"}. (**E**) Flow cytometry analysis at DE stage for SOX17 in control and KO (-/-) cells for indicated lncRNAs. The line demarks isotype control. Percentage of cells expressing SOX17 is indicated (representative experiment, n ≥ 3 independent differentiations from at least two KO clones). (**F**) Immunofluorescence staining for FOXA2 or GATA6 in DE from control and *LINC00261*, *GATA6-AS1*, and *DIGIT* KO cells. (**G**) Immunofluorescence staining for insulin (INS) in endocrine cell stage (EC) from control and KO hESCs for the indicated lncRNAs (representative images, n ≥ 3 independent differentiations from at least two KO clones). Boxed areas (dashed boxes) are shown in higher magnification. (**H**) qRT-PCR analysis of *INS* in EC stage cultures from control and lncRNA KO (-/-) hESCs. Data are shown as mean ± S.E.M. (n ≥ 4 replicates from independent differentiations of at least two KO clones). Individual data points are represented by dots. NS, p-value\>0.05; t-test. See also [Figure 3---source data 4](#fig3sdata4){ref-type="supplementary-material"} (I) Flow cytometry analysis at EC stage for INS in control and KO (-/-) cells for indicated lncRNAs. The line demarks isotype control. Percentage of cells expressing insulin is indicated (representative experiment, n ≥ 3 independent differentiations each from at least two KO clones). Scale bars = 100 µm. See also [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}--[4](#fig3sdata4){ref-type="supplementary-material"}.\
Figure 3---source data 1.Differentially expressed genes after lncRNA deletion.(**A**) Coordinates of CRISPR deletions. (**B**) Differentially expressed genes in *RP11-445F12.1* knockout at definitive endoderm stage. (**C**) Differentially expressed genes in *GATA6-AS1* knockout at definitive endoderm stage. (**D**) Differentially expressed genes in *LINC00261* knockout at definitive endoderm stage. (**E**) Differentially expressed genes in *LINC00617* knockout at PP2 stage. (**F**) Differentially expressed genes in *GATA6-AS1* knockout at PP2 stage. (**G**) Differentially expressed genes in *LINC00479* knockout at PP2 stage. (**H**) Differentially expressed genes in *RP11-834C11.4* knockout at PP2 stage. (**I**) Differentially expressed genes in *SOX9-AS1* knockout at PP2 stage. (**J**) Differentially expressed genes in *MIR7-3HG* knockout at PP2 stage. (**K**) Differentially expressed genes in *LHFPL3-AS2* knockout at PP2 stage.\
Figure 3---source data 2.Source data used for the qRT-PCR quantification of gene expression presented in [Figure 3A](#fig3){ref-type="fig"}.\
Figure 3---source data 3.Source data used for the qRT-PCR quantification of gene expression presented in [Figure 3D](#fig3){ref-type="fig"}.\
Figure 3---source data 4.Source data used for the qRT-PCR quantification of *INS* expression presented in [Figure 3H](#fig3){ref-type="fig"}.](elife-58659-fig3){#fig3}

We next differentiated each of the lncRNA KO hESC lines stepwise toward the pancreatic endocrine cell stage, conducting up to 16 replicate differentiations for each KO clone. Because *LINC00617, RP11-445F12.1, DIGIT, GATA6-AS1*, *LINC00479*, and *LINC00261* were first expressed at, or before, the definitive endoderm stage ([Figure 3A](#fig3){ref-type="fig"}), we determined whether KO hESCs for these lncRNAs exhibited defects in definitive endoderm formation. Despite efficient lncRNA depletion ([Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}), neither quantification of definitive endoderm marker gene expression by qRT-PCR, nor immunofluorescence staining or flow cytometric analysis of the definitive endoderm marker SOX17 showed differences indicative of impaired endoderm formation in lncRNA KO lines ([Figure 3C--E](#fig3){ref-type="fig"}). Importantly, expression of TFs located in the direct vicinity of these lncRNAs, including *GSC* (*DIGIT*), *LHX1* (*RP11-445F12.1)*, *GATA6* (*GATA6-AS1*), and *FOXA2 (LINC00261)*, was unaffected by the lncRNA KO ([Figure 3F](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}, [Figure 3---source data 1B--D](#fig3sdata1){ref-type="supplementary-material"}), arguing against *cis*-regulation by these lncRNAs. These findings are in contrast to prior reports that have shown a requirement for *LINC00261* and *DIGIT* in definitive endoderm formation and the regulation of neighboring TFs *FOXA2* and *GSC*, respectively ([@bib2]; [@bib14]; [@bib19]; [@bib54]).

Next, we further differentiated control and KO lines for eight out of ten lncRNAs toward the endocrine cell stage, excluding *DIGIT* and *RP11-445F12.1* because they are not expressed after the definitive endoderm stage ([Figure 3A](#fig3){ref-type="fig"}). In KO hESC lines of seven out of these eight lncRNAs, we observed no effect on pancreatic progenitor cell formation or gene expression, with the exception of a handful of dysregulated genes in *LHFPL3-AS2* and *RP11-834C11.4* KO cells ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"} and [Figure 3---source data 1E--K](#fig3sdata1){ref-type="supplementary-material"}). Furthermore, deletion of seven out of the eight lncRNAs did not impair endocrine cell formation, as determined by quantification of insulin^+^ cells and insulin mRNA levels ([Figure 3G--I](#fig3){ref-type="fig"}). Similar to the RNA expression results obtained at the definitive endoderm stage, deletion of none of the lncRNAs close to pancreatic TFs (e.g. *GATA6-AS1* and *SOX9-AS1*) altered the expression of these TFs, once more arguing against *cis*-regulation of these TFs by the neighboring lncRNA ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). Thus, nine out of ten endoderm- and pancreatic progenitor-enriched lncRNAs functionally investigated here appear to be nonessential for induction of the pancreatic fate and formation of insulin^+^ cells. Furthermore, these lncRNAs do not appear to control the transcript levels of proximal TFs.

*LINC00261* knockout impairs endocrine cell development {#s2-5}
-------------------------------------------------------

The exception was the endoderm-specific lncRNA *LINC00261*, which is highly expressed and translated in pancreatic progenitors ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"} and [Figure 2C](#fig2){ref-type="fig"}). While deletion of *LINC00261* caused no discernable phenotype in definitive endoderm ([Figure 3C--F](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}), we observed a significant 30--50% reduction in the number of insulin^+^ cells at the endocrine cell stage ([Figure 4A,B](#fig4){ref-type="fig"}). This reduction in insulin^+^ cell numbers was consistent across four separately derived *LINC00261* KO hESC lines, each independently differentiated to endocrine cell stage 5--8 times. In agreement with reduced insulin^+^ cell numbers, insulin content and insulin mRNA levels were also reduced in *LINC00261* KO endocrine stage cultures ([Figure 4C,D](#fig4){ref-type="fig"}). Analysis of insulin median fluorescence intensities by flow cytometry further showed no reduction in insulin levels per cell in one *LINC00261* KO clone and a mild reduction in the three other clones ([Figure 4E](#fig4){ref-type="fig"}), indicating that *LINC00261* predominately regulates endocrine cell differentiation rather than maintenance of insulin production in beta cells.

![*LINC00261* deletion impedes pancreatic endocrine cell differentiation.\
(**A**) Flow cytometry analysis at endocrine cell stage (EC) for insulin (INS) in control (ctrl) and *LINC000261^-/-^* H1 hESCs. Top panel: Schematic of the *LINC00261* locus. The dashed box represents the genomic deletion. Middle panel: The line demarks isotype control. Percentage of cells expressing INS is indicated (representative experiment, n = 4 deletion clones generated with independent sgRNAs). Bottom panel: Bar graph showing percentages of INS-positive cells. Data are shown as mean ± S.D. (n = 5 (clone 1), n = 6 (clone 2), n = 8 (clone 3), n = 5 (clone 4) independent differentiations). Individual data points are represented by dots. (**B**) Immunofluorescence staining for INS in EC stage cultures from control and *LINC000261*^-/-^ hESCs (representative images, number of differentiations see A). Boxed areas (dashed boxes) are shown in higher magnification. (**C**) ELISA for INS in EC stage cultures from control and *LINC00261*^-/-^ hESCs. Data are shown as mean ± S.D. (n = 3 (clone 1), n = 2 (clone 2), n = 14 (clone 3), n = 13 (clone 4) independent differentiations). Individual data points are represented by dots. (**D**) qRT-PCR analysis of *INS* in EC stage cultures from control and *LINC00261*^-/-^ hESCs. Data are shown as mean ± S.E.M. (n = 8 (clone 1), n = 4 (clone 2), n = 10 (clone 3), n = 3 (clone 4) independent differentiations). Individual data points are represented by dots. (**E**) Quantification of median fluorescence intensity after INS staining of control and *LINC00261*^-/-^ EC stage cultures. Data are shown as mean ± S.D. (n = 5 (clone 1), n = 5 (clone 2), n = 4 (clone 3), n = 4 (clone 4) independent differentiations). iso, isotype control. Individual data points are represented by dots. (**F**) Volcano plot displaying gene expression changes in control versus *LINC00261*^-/-^ PP2 cells (n = 6 independent differentiations from all four deletion clones). Differentially expressed genes are shown in red (DESeq2;\>2 fold change (FC), adjusted p-value\<0.01) and blue (\>2 fold change, adjusted p-value≥0.01 and≤0.05). Thresholds are represented by vertical and horizontal dashed lines. *FOXA2* in cis to *LINC00261* is shown in gray (gray dots represent genes with ≤ 2 fold change and/or adjusted p-value\>0.05). (**G**) Circos plot visualizing the chromosomal locations of the 108 genes differentially expressed (DESeq2;\>2 fold change (FC), adjusted p-value\<0.01) in *LINC00261*^-/-^ compared to control PP2 cells, relative to *LINC00261* on chromosome 20. No chromosome was over- or underrepresented (Fisher test, p-value\>0.05 for all chromosomes). (**H**) Top panel: Schematic of the *LINC00261* locus, with the location of its sORFs (1 to 7) marked by vertical red bars. Bottom panel: Flow cytometric quantification of INS-positive cells in control and *LINC00261*-sORF-frameshift (FS) at the EC stage. Data are shown as mean ± S.D. (n = 4--7 independent differentiations per clone). (**I**) ELISA for INS in EC stage cultures from control and *LINC00261*-sORF-FS hESCs. Data are shown as mean ± S.D. (n = 3--7 independent differentiations per clone). (**J**) Volcano plot displaying gene expression changes in control versus *LINC00261*-sORF3-FS PP2 cells. No gene was differentially expressed (DESeq2;\>2 fold change, adjusted p-value\<0.01; indicated by dashed horizontal and vertical lines; n = 2 independent differentiations). *LINC00261* is shown in gray, the bar graph insert displays *LINC00261* RPKM values in control and *LINC00261*-sORF3-FS PP2 cells. (**K**) *LINC00261* half-life measurements in HEK293T cells transduced with lentivirus expressing either wild type (WT) *LINC00261* or ΔATG^sORF1-7^ *LINC00261* (mutant in which the ATG start codons of sORFs 1--7 were changed to non-start codons). HEK293T were treated with the transcription inhibitor actinomycin D and RNA isolated at 0, 2, 4, 6, 8, and 9 hr post actinomycin D addition. *LINC00261* expression was analyzed by qRT-PCR relative to the *TBP* gene. Data are shown as mean ± S.E.M. (n = 3 biological replicates for each assay time point). \*, p-value\<0.05; \*\*, p-value\<0.01; \*\*\*, p-value\<0.001; \*\*\*\*, p-value\<0.0001; NS, p-value\>0.05; t-test. Scale bars = 100 µm. See also [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} and [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}--[3](#fig4sdata3){ref-type="supplementary-material"}.\
Figure 4---source data 1.Characterization of *LINC00261* knockout and *LINC00261*-sORF3-frameshift PP2 cells.(**A**) Differentially expressed genes in *LINC00261* knockout PP2 stage cells. (**B**) Sequences of *LINC00261* wild type and frameshift mutants. (**C**) Differentially expressed genes in *LINC00261*-sORF3-frameshift PP2 stage cells.\
Figure 4---source data 2.List of oligonucleotides and synthetic gene fragments used in this study.(**A**) sgRNA oligonucleotides used for cloning into PX458/Px459. (**B**) Genotyping and sequencing primers for KO validation. (**C**) qRT-PCR primers. (**D**) Cloning primers (translation reporter constructs and lentiviral *LINC00261* overexpression plasmids). (**E**) Synthetic gene fragments. (**F**) Custom *LINC00261* Stellaris RNA FISH probe set.\
Figure 4---source data 3.Source data used for the insulin measurements presented in [Figure 4](#fig4){ref-type="fig"}.](elife-58659-fig4){#fig4}

To determine the molecular effects of *LINC00261* deletion, we performed RNA-seq in pancreatic progenitors derived from *LINC00261* KO and control hESCs. Similar to the absence of *cis*-regulatory functions observed in the other lncRNA KOs, we found no evidence for *cis*-regulation of *FOXA2* by *LINC00261* ([Figure 4F](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). However, we observed downregulation of the TFs *MAFB* and *PAX4* ([Figure 4F](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}, [Figure 4---source data 1A](#fig4sdata1){ref-type="supplementary-material"}), which are important regulators of beta cell differentiation ([@bib5]; [@bib52]). Of note, genes differentially expressed in *LINC00261* KO cells mapped to all chromosomes and showed no enrichment for chromosome 20 where *LINC00261* resides ([Figure 4G](#fig4){ref-type="fig"}). These results suggest a *trans-* rather than *cis*-regulatory function for *LINC00261*, consistent with its predominantly cytosolic localization, translation, and diffuse distribution within the nucleus ([Figure 2C](#fig2){ref-type="fig"} and [Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). *Trans-*regulatory roles of *LINC00261* have also been observed in previous studies ([@bib1]; [@bib50]; [@bib61]; [@bib60]; [@bib63]). This potential *trans* functionality prompted us to further investigate whether *LINC00261*\'s coding or noncoding features are essential for endocrine cell differentiation.

One-by-one disruption of *LINC00261*\'s sORFs does not impact endocrine cell differentiation {#s2-6}
--------------------------------------------------------------------------------------------

We established that *LINC00261* harbors multiple distinct and highly translated sORFs, which raises the possibility that the translation of these sORFs is functionally important for endocrine cell differentiation. To systematically discriminate *LINC00261*\'s coding and noncoding roles, we individually mutated its seven most highly translated sORFs independently in hESCs, leaving the lncRNA sequence, and hence any noncoding function coupled to RNA sequence or structure, grossly intact. Each of these hESC lines either carried a homozygous frameshift mutation near the microprotein\'s N-terminus (for sORFs 1--6) or a full sORF deletion (sORF7; [Figure 4---source data 1B](#fig4sdata1){ref-type="supplementary-material"}). After verifying that CRISPR editing of the *LINC00261* locus did not impact *LINC00261* transcript levels ([Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}), we quantified (i) insulin mRNA levels, (ii) insulin^+^ cells, and (iii) total insulin content in endocrine cell stage cultures. We observed no difference between sORF loss-of-function and control hESC lines for most of these endpoints ([Figure 4H,I](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}), although we noticed that the number of insulin^+^ cells, but not the amount of insulin produced, was reduced in one of the two sORF4 and sORF7 KO clones. Transcriptome analysis of pancreatic progenitors with frameshifts in sORF3 (the most highly translated *LINC00261*-sORF; [Figure 2C](#fig2){ref-type="fig"} and [Figure 2---source data 1D](#fig2sdata1){ref-type="supplementary-material"}) revealed no differentially expressed genes between *LINC00261*-sORF3 frameshift and control cells ([Figure 4J](#fig4){ref-type="fig"} and [Figure 4---source data 1C](#fig4sdata1){ref-type="supplementary-material"}), contrasting observations in *LINC00261* RNA KO pancreatic progenitors ([Figure 4F](#fig4){ref-type="fig"} and [Figure 4---source data 1A](#fig4sdata1){ref-type="supplementary-material"}). These results indicate that there is not one dominant *LINC00261* sORF that is required for endocrine cell formation, suggesting a functional role of the *LINC00261* transcript and not the individual sORFs mutated here. However, it is possible that the different sORFs, or the microproteins translated from these sORFs, are functionally redundant and capable of phenotypic rescue.

It has been suggested that ribosome association can control lncRNA transcript levels by inducing nonsense-mediated decay (NMD) ([@bib11]; [@bib55]). Therefore, we determined whether the presence of multiple sORFs could regulate *LINC00261* stability. To this end, we simultaneously mutated start codons of all seven sORFs (ΔATG^sORF1-7^ *LINC00261*) and expressed either wild type or ΔATG^sORF1-7^ *LINC00261* ectopically in HEK293T cells, where *LINC00261* is normally not expressed. *LINC00261* half-life measurements upon transcriptional inhibition with actinomycin D revealed no difference in *LINC00261* levels between wild type and ΔATG^sORF1-7^ *LINC00261* ([Figure 4K](#fig4){ref-type="fig"}), suggesting that the translation of the seven sORFs does not reduce *LINC00261* transcript stability.

In sum, through the systematic, one-by-one removal of sORFs within a highly translated lncRNA with functional importance for pancreatic endocrine cell formation, we found no evidence to implicate the individual sORFs, or the microproteins they produce, in endocrine cell development. Although *LINC00261*\'s sORFs may share functional redundancy or have developmental roles that do not affect the production of insulin^+^ cells, our findings strongly suggest that by themselves, these sORFs are not functionally required for endocrine cell formation.

Discussion {#s3}
==========

Limited *cis*-regulatory consequences of lncRNA deletion {#s3-1}
--------------------------------------------------------

In this study we globally characterized molecular features of lncRNAs expressed during progression of hESCs toward the pancreatic lineage, including their subcellular localization and potential to be translated. We performed a phenotypic CRISPR loss-of-function screen, focusing on ten developmentally regulated, highly expressed, and highly translated lncRNAs proximal to TFs known to regulate pancreas development. The first important observation from this screen is that we found no evidence to implicate the lncRNAs *LINC00261, DIGIT*, *GATA6-AS1, SOX9-AS1*, and *RP11-445F12.1* in the *cis*-regulation of their neighboring TFs *FOXA2*, *GSC*, *GATA6*, *SOX9,* and *LHX*, respectively, despite tight transcriptional coregulation of the lncRNA-TF pairs.

Contrasting our findings, a number of studies have reported *cis*-regulation of *FOXA2* by *LINC00261* ([@bib2]; [@bib19]; [@bib54]). However, several lines of evidence strongly support the conclusion that *FOXA2* is not regulated by *LINC00261* in our experimental system. First, we examined *FOXA2* mRNA expression in *LINC000261*^-/-^ cells at both the definitive endoderm and pancreatic progenitor cell stages. Second, we analyzed *FOXA2* expression using two independent methods, namely qRT-PCR and RNA-seq. Third, immunofluorescence staining in definitive endoderm revealed no difference in FOXA2 protein expression between control and *LINC00261*^-/-^ cells.

While different cellular contexts and species could explain the discrepancy between our findings and the ones by [@bib2] and [@bib54], [@bib19] reported *FOXA2* regulation by *LINC00261* in hESC-derived definitive endoderm. One important difference between our study and the study by Jiang et al. is that we employed CRISPR-Cas9-mediated deletion, whereas Jiang et al. used shRNA-mediated knockdown to inactivate *LINC00261*. It is possible that lncRNA deletion triggers compensatory mechanisms that are not activated after shRNA-mediated knockdown. For coding genes, mutant mRNA degradation has been shown to trigger genetic compensation ([@bib16]). Another difference between our study and the one by Jiang et al. is that our differentiation protocol was more efficient in generating definitive endoderm. It is conceivable that the stability of the cell fate and identity of neighboring cells could influence how *LINC00261* loss-of-function affects gene regulation.

Translation of short, non-canonical ORFs in lncRNAs: regulatory, microprotein-producing, or just tolerated? {#s3-2}
-----------------------------------------------------------------------------------------------------------

Although lncRNAs are now appreciated as a novel and abundant source of sORF-encoded biologically active microproteins ([@bib30]), it remains largely unknown which translation events lead to the production of microproteins, which solely have regulatory potential, or which have no functional roles, but are not negatively selected against. The cytosolic localization and translation of many RNAs classified as lncRNAs provides a strong rationale for considering both, coding and noncoding functions.

In this study, we identified the translated lncRNA *LINC00261* as a novel regulator of pancreatic endocrine cell differentiation, as evidenced by a severe reduction in insulin^+^ cell numbers upon *LINC00261* deletion. We show that *LINC00261* transcripts are highly abundant in pancreatic progenitors and, albeit present in the nucleus, are predominantly localized to the cytoplasm. Here, they frequently associate with ribosomes which leads to the translation of multiple independent sORFs. We show that the sORFs are capable of producing microproteins with distinct subcellular localizations upon expression in vitro. In contrast to *LINC00261* deletion, individual frameshift mutations in each of *LINC00261*\'s sORFs did not impair endocrine cell development, suggesting that the requirement of *LINC00261* for endocrine cell development can be uncoupled from the translation of its multiple sORFs. However, this does not exclude the possibility that these sORFs or the microproteins they produce could possess functions that become relevant under specific environmental, developmental, or disease conditions not examined in this study.

We found that mutating all translated *LINC00261* sORFs simultaneously, thereby likely reducing *LINC00261*\'s ability to bind ribosomes, did not affect *LINC00261* transcript levels in HEK293T cells. This indicates that, in contrast to reports suggesting that translated sORFs can regulate RNA stability by promoting nonsense-mediated RNA decay ([@bib11]; [@bib55]), the high translation levels and multiple sORFs of *LINC00261* are unlikely to be part of a *LINC00261* decay pathway. It would have been interesting to determine how concurrent mutation of all sORFs in *LINC00261* affects pancreatic cell differentiation. However, given the size of the *LINC00261* locus and the many sORFs, such an approach comes with technical challenges and significant caveats.

*LINC00261* - a potential *trans* regulator of endocrine cell differentiation? {#s3-3}
------------------------------------------------------------------------------

Several lines of evidence suggest that *LINC00261* regulates endocrine cell differentiation in trans: (i) *LINC00261* transcripts show a diffuse distribution in multiple subcellular compartments, (ii) genes differentially expressed in *LINC00261* KO cells are randomly distributed throughout the genome, (iii) expression of the nearby TF *FOXA2* is not affected by *LINC00261* deletion. Such a *trans* regulatory mechanism for *LINC00261* is supported by a recent study from the GTEx Consortium, where *LINC00261* is highlighted as one of a few lncRNAs that forms a potential *trans* regulatory hotspot through genetic interactions that influence the expression of multiple distant genes ([@bib1]). Consistent with its preferential cytosolic localization, and further supporting the notion of a *trans* regulatory mechanism, *LINC00261* has been suggested to regulate gene expression through non-nuclear mechanisms, e.g. by preventing nuclear translocation of β-catenin ([@bib60]) or by acting as a miRNA sponge ([@bib50]; [@bib61]; [@bib63]). Although our observations and current literature strongly hint to a function in trans independent of the produced microproteins, the exact mechanism by which *LINC00261* regulates gene expression in pancreatic progenitors remains to be determined.

Limitations and future directions {#s3-4}
---------------------------------

In this study, we have characterized the role of translated lncRNAs, and in particular *LINC00261,* in a hESC differentiation system that mimics pancreas development. However, there are several potential limitations that need to be considered when interpreting the results. First, a small subset of analyses in this study was based on low numbers of replicate differentiations, in particular the cytosolic versus nuclear fractionation RNA-seq experiments, where only two replicate differentiations into pancreatic progenitor cells were analyzed. Second, although we provide evidence that *LINC00261* can produce microproteins using Ribo-seq, which is further supported by in vitro translation assays and overexpression of *LINC00261* constructs with different in-frame tags, we provide no protein-level evidence for the endogenous production and stability of *LINC00261*\'s microproteins in this differentiation system or in human pancreas development in vivo. Moreover, due to its highly specific expression pattern, *LINC00261* has not been previously detected by sORF analyses in other cell types ([@bib8]; [@bib10]; [@bib12]; [@bib18]; [@bib32]; [@bib38]; [@bib40]; [@bib59]). Even though we show microprotein production in vitro, it is possible that the act of translation has a key regulatory role rather than the protein products of *LINC00261's* sORFs. Lastly, *LINC00261*\'s microproteins and sORFs may have redundant functions, which could explain why deletion of individual sORFs produces no apparent phenotype. Thus, despite limited sequence similarity and stark differences in translation rates between the identified translated sORFs in *LINC00261*, we cannot rule out that different microproteins produced by *LINC00261* compensate when one sORF is deleted. Future studies of *LINC00261*\'s precise mechanisms of action could be aimed at further dissecting the potential regulatory features of sORF translation and possibility of redundancy between sORFs.

Conclusions {#s3-5}
-----------

In summary, we here present a rigorous, in-depth characterization of dynamically regulated and translated lncRNAs in a disease-relevant cell model of human developmental progression. Our combination of ultra-high-coverage RNA- and Ribo-seq, in vitro protein-level validation of microprotein production and localization, and the systematic, one-by-one deletion of all individual microproteins encoded by a single translated lncRNA, not only provides a detailed resource of translated \'non-canonical\' sORFs and their microproteins in pancreatic development, but also serves as a blueprint for the systematic functional interrogation of translated lncRNAs.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                    Designation                                                                                                                     Source or\                                                                 Identifiers                                                                       Additional\
  (species)\                                                                                                                                                                       reference                                                                                                                                                    information
  or resource                                                                                                                                                                                                                                                                                                                                   
  ------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- --------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
  Gene (*Homo sapiens*)                            *LINC00617; TUNAR*                                                                                                              Ensembl 87                                                                 ENSG00000250366                                                                   

  Gene (*Homo sapiens*)                            *RP11-445F12.1; LHX-DT*                                                                                                         Ensembl 87                                                                 ENSG00000250366                                                                   

  Gene (*Homo sapiens*)                            *DIGIT; GSC-DT*                                                                                                                 HGNC and NCBI RefSeq\                                                      HGNC:53074; NCBI RefSeq 108868751                                                 
                                                                                                                                                                                                                                                                                                                                                

  Gene (*Homo sapiens*)                            *GATA6-AS1; GATA6-AS*                                                                                                           Ensembl 87                                                                 ENSG00000277268                                                                   

  Gene (*Homo sapiens*)                            *LINC00479*                                                                                                                     Ensembl 87                                                                 ENSG00000236384                                                                   

  Gene (*Homo sapiens*)                            *LINC00261; DEANR1; ALIEN; onco-lncRNA-17; lnc-FOXA2-2*                                                                         Ensembl 87                                                                 ENSG00000236384                                                                   

  Gene (*Homo sapiens*)                            *RP11-834C11.4*                                                                                                                 Ensembl 87                                                                 ENSG00000250742                                                                   

  Gene (*Homo sapiens*)                            *SOX9-AS1*                                                                                                                      Ensembl 87                                                                 ENSG00000234899                                                                   

  Gene (*Homo sapiens*)                            *MIR7-3HG*                                                                                                                      Ensembl 87                                                                 ENSG00000176840                                                                   

  Gene (*Homo sapiens*)                            *LHFPL3-AS2*                                                                                                                    Ensembl 87                                                                 ENSG00000225329                                                                   

  Strain, strain background (*Escherichia coli*)   Stbl3                                                                                                                           ThermoFisher Scientific                                                    Cat\# C737303                                                                     Chemically competent cells

  Strain, strain background (*Escherichia coli*)   DH5α                                                                                                                            New England Biolabs                                                        Cat\# C2987I                                                                      Chemically competent cells

  Cell line (*Homo sapiens*)                       H1 (embryonic stem cells)                                                                                                       WiCell Research Institute                                                  NIHhESC-10--0043, RRID:[CVCL_9771](https://scicrunch.org/resolver/CVCL_9771)      

  Cell line (*Homo sapiens*)                       HEK293T (embryonic kidney)                                                                                                      ATCC                                                                       Cat\# CRL-3216, RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)        

  Antibody                                         anti-human OCT-4A (Rabbit monoclonal)                                                                                           Cell Signaling Technology                                                  Cat\# 2890,\                                                                      IF (1:1000)
                                                                                                                                                                                                                                                              RRID:[AB_2167725](https://scicrunch.org/resolver/AB_2167725)                      

  Antibody                                         anti-human SOX17 (Goat polyclonal)                                                                                              R and D Systems                                                            Cat\# AF1924,\                                                                    IF (1:250)
                                                                                                                                                                                                                                                              RRID:[AB_355060](https://scicrunch.org/resolver/AB_355060)                        

  Antibody                                         anti-human FOXA2 (Goat polyclonal)                                                                                              Santa Cruz Biotechnology                                                   Cat\# sc-6554, RRID:[AB_2262810](https://scicrunch.org/resolver/AB_2262810)       IF (1:250)

  Antibody                                         anti-human GATA6 (Goat polyclonal)                                                                                              Santa Cruz Biotechnology                                                   Cat\# sc-9055, RRID:[AB_2108768](https://scicrunch.org/resolver/AB_2108768)       IF (1:50)

  Antibody                                         anti-human\                                                                                                                     Dako                                                                       Cat\# A0564, RRID:[AB_10013624](https://scicrunch.org/resolver/AB_10013624)       IF (1:1000)
                                                   Insulin (Guinea pig polyclonal)                                                                                                                                                                                                                                                              

  Antibody                                         Alexa Fluor 488 AffiniPure anti-Goat IgG (Donkey polyclonal)                                                                    Jackson ImmunoResearch Labs                                                Cat\# 706-545-148, RRID:[AB_2340472](https://scicrunch.org/resolver/AB_2340472)   IF (1:1000)

  Antibody                                         Alexa Fluor 488 AffiniPure anti-Rabbit IgG (Donkey polyclonal)                                                                  Jackson ImmunoResearch Labs                                                Cat\# 711-545-152, RRID:[AB_2313584](https://scicrunch.org/resolver/AB_2313584)   IF (1:1000)

  Antibody                                         Cy3 AffiniPure anti-Goat IgG (Donkey polyclonal)                                                                                Jackson ImmunoResearch Labs                                                Cat\# 705-165-147, RRID:[AB_2307351](https://scicrunch.org/resolver/AB_2307351)   IF (1:1000)

  Antibody                                         anti-human Insulin-PE (Rabbit monoclonal)                                                                                       Cell Signaling Technology                                                  Cat\# 8508S, RRID:[AB_11179076](https://scicrunch.org/resolver/AB_11179076)       Flow cytometry (1:50)

  Antibody                                         anti-human SOX17-PE (Mouse monoclonal)                                                                                          BD Biosciences                                                             Cat\# 561591, RRID:[AB_10717121](https://scicrunch.org/resolver/AB_10717121)      Flow cytometry (5 ul per test)

  Antibody                                         IgG-PE (Rabbit monoclonal)                                                                                                      Cell Signaling Technology                                                  Cat\# 5742S, RRID:[AB_10694219](https://scicrunch.org/resolver/AB_10694219)       Flow cytometry isotype control antibody (1:50)

  Antibody                                         IgG1, κ antibody (Mouse monoclonal)                                                                                             BD Biosciences                                                             Cat\# 556650, RRID:[AB_396514](https://scicrunch.org/resolver/AB_396514)          Flow cytometry isotype control antibody (1:50)

  Recombinant DNA reagent                          pSpCas9(BB)−2A-Puro (Px459; V2.0)                                                                                               Feng Zhang                                                                 RRID:[Addgene_62988](https://scicrunch.org/resolver/Addgene_62988)                Cas9 from *S. pyogenes* with 2A-Puro, and cloning backbone for sgRNA

  Recombinant DNA reagent                          [pSpCas9(BB)−](http://www.addgene.org/48138/)[2](http://www.addgene.org/48138/)[A-GFP (PX458)](http://www.addgene.org/48138/)   Feng Zhang                                                                 RRID:[Addgene_48138](https://scicrunch.org/resolver/Addgene_48138)                Cas9 from *S. pyogenes* with 2A-EGFP, and cloning backbone for sgRNA

  Recombinant DNA reagent                          pCMVR8.74                                                                                                                       Didier Trono                                                               RRID:[Addgene_22036](https://scicrunch.org/resolver/Addgene_22036)                2nd generation lentiviral packaging plasmid

  Recombinant DNA reagent                          pMD2.G                                                                                                                          Didier Trono                                                               RRID:[Addgene_12259](https://scicrunch.org/resolver/Addgene_12259)                VSV-G envelope expressing plasmid

  Recombinant DNA reagent                          pENTR/D-TOPO-*LINC00261*                                                                                                        [@bib22] (PMID:[25739401](https://www.ncbi.nlm.nih.gov/pubmed/25739401))                                                                                     Leo Kurian (University of Cologne)

  Recombinant DNA reagent                          pRRLSIN.cPPT.PGK-GFP.WPRE                                                                                                       Didier Trono                                                               RRID:[Addgene_12252](https://scicrunch.org/resolver/Addgene_12252)                3rd generation lentiviral backbone

  Recombinant DNA reagent                          pRRLSIN.cPPT.PGK-*LINC00261*.WPRE                                                                                               This paper                                                                                                                                                   Transient (transfection) or stable (lentiviral integration) expression of wild type *LINC00261*

  Recombinant DNA reagent                          pRRLSIN.cPPT.PGK-ΔATG^sORF1-7^ *LINC00261*.WPRE                                                                                 This paper                                                                                                                                                   Transient (transfection) or stable (lentiviral integration) expression of ΔATG^sORF1-7^ *LINC00261*

  Recombinant DNA reagent                          pRRLSIN.cPPT.PGK-*LINC00261-sORF1-GFP*.WPRE                                                                                     This paper                                                                                                                                                   Transient (transfection) or stable (lentiviral integration) expression of *LINC00261-sORF1-GFP* fusion protein

  Recombinant DNA reagent                          pRRLSIN.cPPT.PGK-*LINC00261-sORF2-GFP*.WPRE                                                                                     This paper                                                                                                                                                   Transient (transfection) or stable (lentiviral integration) expression of *LINC00261-sORF2-GFP* fusion protein

  Recombinant DNA reagent                          pRRLSIN.cPPT.PGK-*LINC00261-sORF3-GFP*.WPRE                                                                                     This paper                                                                                                                                                   Transient (transfection) or stable (lentiviral integration) expression of *LINC00261-sORF3-GFP fusion protein*

  Recombinant DNA reagent                          pRRLSIN.cPPT.PGK-*LINC00261-sORF4-GFP*.WPRE                                                                                     This paper                                                                                                                                                   Transient (transfection) or stable (lentiviral integration) expression of *LINC00261-sORF4-GFP* fusion protein

  Recombinant DNA reagent                          pRRLSIN.cPPT.PGK-*LINC00261-sORF5-GFP*.WPRE                                                                                     This paper                                                                                                                                                   Transient (transfection) or stable (lentiviral integration) expression of *LINC00261-sORF5-GFP* fusion protein

  Recombinant DNA reagent                          pRRLSIN.cPPT.PGK-*LINC00261-sORF6-GFP*.WPRE                                                                                     This paper                                                                                                                                                   Transient (transfection) or stable (lentiviral integration) expression of *LINC00261-sORF6-GFP* fusion protein

  Recombinant DNA reagent                          pRRLSIN.cPPT.PGK-*LINC00261-sORF7-GFP*.WPRE                                                                                     This paper                                                                                                                                                   Transient (transfection) or stable (lentiviral integration) expression of *LINC00261-sORF7-GFP* fusion protein

  Recombinant DNA reagent                          pRRLSIN.cPPT.PGK-*LINC00261-sORF3-FS-GFP*.WPRE                                                                                  This paper                                                                                                                                                   *LINC00261-sORF3-frameshift-GFP* control plasmid

  Recombinant DNA reagent                          pRRLSIN.cPPT.PGK-*LINC00261-sORF2-STOP-GFP*.WPRE                                                                                This paper                                                                                                                                                   *LINC00261-sORF2-STOP-GFP* control plasmid

  Recombinant DNA reagent                          pRRLSIN.cPPT.PGK-*RP11-834C11.4-sORF-GFP*.WPRE                                                                                  This paper                                                                                                                                                   Transient (transfection) or stable (lentiviral integration) expression of *RP11-834C11.4-sORF-GFP* fusion protein

  Recombinant DNA reagent                          pRRLSIN.cPPT.PGK-*RP11-834C11.4-sORF-FLAG*.WPRE                                                                                 This paper                                                                                                                                                   Transient (transfection) or stable (lentiviral integration) expression of *RP11-834C11.4-sORF-FLAG* fusion protein

  Recombinant DNA reagent                          pRRLSIN.cPPT.PGK-*MIR7-3HG-sORF-GFP*.WPRE                                                                                       This paper                                                                                                                                                   Transient (transfection) or stable (lentiviral integration) expression of *MIR7-3HG-sORF-GFP* fusion protein

  Recombinant DNA reagent                          pRRLSIN.cPPT.PGK-*RP11-LHFPL3-AS2-sORF-GFP*.WPRE                                                                                This paper                                                                                                                                                   Transient (transfection) or stable (lentiviral integration) expression of *LHFPL3-AS2-sORF-GFP* fusion protein

  Peptide, recombinant protein                     Activin A                                                                                                                       R and D Systems                                                            Cat\# 338-AC/CF                                                                   

  Peptide, recombinant protein                     Wnt3a                                                                                                                           R and D Systems                                                            Cat\# 1324-WN-010                                                                 

  Peptide, recombinant protein                     KGF/FGF7                                                                                                                        R and D Systems                                                            Cat\# 251 KG                                                                      

  Peptide, recombinant protein                     Noggin                                                                                                                          R and D Systems                                                            Cat\# 3344 NG-050                                                                 

  Commercial assay or kit                          RNeasy\                                                                                                                         QIAGEN                                                                     Cat\# 15596018                                                                    
                                                   Mini Kit                                                                                                                                                                                                                                                                                     

  Commercial assay or kit                          RNA Clean and Concentrator−25                                                                                                   Zymo Research                                                              Cat\# R1018                                                                       

  Commercial assay or kit                          Paris Kit                                                                                                                       Thermo Fisher\                                                             Cat\# AM1921                                                                      
                                                                                                                                                                                   Scientific                                                                                                                                                   

  Commercial assay or kit                          RNase-Free DNase Set (50)                                                                                                       QIAGEN                                                                     Cat\# 79254                                                                       

  Commercial assay or kit                          TURBO DNA-free Kit                                                                                                              Thermo Fisher Scientific                                                   Cat\# AM1907                                                                      

  Commercial assay or kit                          TruSeq Ribo Profile (Mammalian) Library Prep Kit                                                                                Illumina                                                                   Cat\# RPYSC12116                                                                  

  Commercial assay or kit                          TruSeq Stranded mRNA Library Prep                                                                                               Illumina                                                                   Cat\# 20020594                                                                    

  Commercial assay or kit                          TruSeq Stranded Total RNA Library Prep Gold                                                                                     Illumina                                                                   Cat\# 20020599                                                                    

  Commercial assay or kit                          KAPA mRNA HyperPrep Kit                                                                                                         Roche                                                                      Cat\# KK8581                                                                      

  Commercial assay or kit                          High Sensitivity D1000 ScreenTape                                                                                               Agilent Technologies                                                       Cat\# 5067--5584                                                                  

  Commercial assay or kit                          RNA ScreenTape                                                                                                                  Agilent Technologies                                                       Cat\# 5067--5576                                                                  

  Commercial assay or kit                          RNA ScreenTape Sample Buffer                                                                                                    Agilent Technologies                                                       Cat\# 5067--5577                                                                  

  Commercial assay or kit                          RNA ScreenTape Ladder                                                                                                           Agilent Technologies                                                       Cat\# 5067--5578                                                                  

  Commercial assay or kit                          Qubit ssDNA assay kit                                                                                                           Thermo Fisher Scientific                                                   Cat\# Q10212                                                                      

  Commercial assay or kit                          KOD Xtreme DNA Hotstart Polymerase                                                                                              Millipore                                                                  Cat\# 71975                                                                       

  Commercial assay or kit                          GoTaq Green Master Mix                                                                                                          Promega                                                                    Cat\# M7123                                                                       

  Commercial assay or kit                          TOPO TA Cloning Kit                                                                                                             Thermo Fisher Scientific                                                   Cat\# K452001                                                                     

  Commercial assay or kit                          Monarch Plasmid Miniprep Kit                                                                                                    NEB                                                                        Cat\# T1010L                                                                      

  Commercial assay or kit                          MinElute PCR Purification Kit                                                                                                   QIAGEN                                                                     Cat\# 28006                                                                       

  Commercial assay or kit                          iScript cDNA Synthesis Kit                                                                                                      Bio-Rad                                                                    Cat\# 1708890                                                                     

  Commercial assay or kit                          iQ SYBR Green Supermix                                                                                                          Bio-Rad                                                                    Cat\# 1708880                                                                     

  Commercial assay or kit                          Human Stem Cell\                                                                                                                Lonza                                                                      Cat\# VPH-5022                                                                    
                                                   Nucleofector Kit 2                                                                                                                                                                                                                                                                           

  Commercial assay or kit                          XtremeGene 9 DNA Transfection Reagent                                                                                           Sigma-Aldrich                                                              Cat\# 06365779001                                                                 

  Commercial assay or kit                          Cytofix/Cytoperm W/Golgi Stop Kit                                                                                               BD Biosciences                                                             Cat\# 554715                                                                      

  Commercial assay or kit                          Insulin ELISA Jumbo                                                                                                             Alpco                                                                      Cat\# 80-INSHU-E10.1                                                              

  Commercial assay or kit                          Pierce BCA Protein Assay Kit                                                                                                    Thermo Fisher Scientific                                                   Cat\# 23227                                                                       

  Commercial assay or kit                          TnT Coupled Wheat Germ Extract System                                                                                           Promega                                                                    Cat\# L4130                                                                       

  Chemical compound, drug                          Penicillin-Streptomycin                                                                                                         Thermo Fisher Scientific                                                   Cat\# 15140122                                                                    

  Chemical compound, drug                          Puromycin dihydrochloride                                                                                                       Sigma-Aldrich                                                              Cat\# P8833                                                                       

  Chemical compound, drug                          ALK5 Inhibitor II                                                                                                               Enzo Life Sciences                                                         Cat\# ALX-270--445                                                                

  Chemical compound, drug                          Retinoic Acid                                                                                                                   Sigma-Aldrich                                                              Cat\# R2625                                                                       

  Chemical compound, drug                          Ascorbic Acid                                                                                                                   Sigma-Aldrich                                                              Cat\# A4403-100MG                                                                 

  Chemical compound, drug                          LDN-193189                                                                                                                      Stemgent                                                                   Cat\# 04--0074                                                                    

  Chemical compound, drug                          SANT-1                                                                                                                          Sigma-Aldrich                                                              Cat\# S4572                                                                       

  Chemical compound, drug                          TPB                                                                                                                             Calbiochem                                                                 Cat\# 565740                                                                      

  Chemical compound, drug                          TGFβ R1 kinase inhibitor IV                                                                                                     EMD Biosciences                                                            Cat\# 616454                                                                      

  Chemical compound, drug                          KAAD-Cyclopamine                                                                                                                Toronto Research Chemicals                                                 Cat\# K171000                                                                     

  Chemical compound, drug                          TTNPB                                                                                                                           Sigma-Aldrich                                                              Cat\# T3757                                                                       

  Chemical compound, drug                          Cycloheximide                                                                                                                   Sigma-Aldrich                                                              Cat\# C7698                                                                       

  Chemical compound, drug                          Actinomycin D                                                                                                                   Sigma-Aldrich                                                              Cat\# A9415                                                                       

  Chemical compound,\                              Polyethylenimine (PEI)                                                                                                          Polysciences                                                               Cat\# 23966--1                                                                    
  drug                                                                                                                                                                                                                                                                                                                                          

  Chemical compound, drug                          Hoechst 33342, Trihydrochloride, Trihydrate                                                                                     Thermo Fisher Scientific                                                   Cat\# H3570                                                                       

  Chemical\                                        MitoSOX Red                                                                                                                     Thermo Fisher Scientific                                                   Cat\# M36008                                                                      
  compound, drug                                                                                                                                                                                                                                                                                                                                

  Chemical compound, drug                          D-(+)-Glucose Solution, 45%                                                                                                     Sigma-Aldrich                                                              Cat\# G8769                                                                       

  Chemical compound, drug                          Sodium Bicarbonate                                                                                                              Sigma-Aldrich                                                              Cat\# NC0564699                                                                   

  Chemical compound, drug                          ROCK Inhibitor Y-27632                                                                                                          STEMCELL Technologies                                                      Cat\# 72305                                                                       

  Software, algorithm                              Flowjo-v10                                                                                                                      FlowJo, LLC                                                                RRID:[SCR_008520](https://scicrunch.org/resolver/SCR_008520)                      <http://www.flowjo.com/download-newest-version/>

  Software, algorithm                              STAR 2.5.3a                                                                                                                     [@bib15]                                                                   RRID:[SCR_015899](https://scicrunch.org/resolver/SCR_015899)                      <https://github.com/alexdobin/STAR>

  Software, algorithm                              Bowtie 1.1.1                                                                                                                    [@bib23]                                                                   RRID:[SCR_005476](https://scicrunch.org/resolver/SCR_005476)                      <http://bowtie-bio.sourceforge.net/index.shtml>

  Software, algorithm                              Cufflinks 2.2.1                                                                                                                 [@bib57]                                                                   RRID:[SCR_014597](https://scicrunch.org/resolver/SCR_014597)                      <https://github.com/cole-trapnell-lab/cufflinks>

  Software, algorithm                              HTSeq 0.6.1                                                                                                                     [@bib3]                                                                    RRID:[SCR_005514](https://scicrunch.org/resolver/SCR_005514)                      <https://htseq.readthedocs.io/en/master/install.html>

  Software, algorithm                              DEseq2 1.10.1                                                                                                                   [@bib28]                                                                   RRID:[SCR_015687](https://scicrunch.org/resolver/SCR_015687)                      <https://www.bioconductor.org/packages/devel/bioc/html/DESeq2.html>

  Software, algorithm                              RiboTaper                                                                                                                       [@bib10]                                                                   RRID:[SCR_018880](https://scicrunch.org/resolver/SCR_018880)                      <https://ohlerlab.mdc-berlin.de/software/RiboTaper_126/>

  Software, algorithm                              R 3.5.0                                                                                                                                                                                                    RRID:[SCR_001905](https://scicrunch.org/resolver/SCR_001905)                      <https://cran.r-project.org/>

  Software, algorithm                              SAMtools 1.3                                                                                                                    [@bib25]                                                                   RRID:[SCR_002105](https://scicrunch.org/resolver/SCR_002105)                      <https://github.com/samtools/samtools>

  Software, algorithm                              BEDTools 2.17.0                                                                                                                 [@bib39]                                                                   RRID:[SCR_006646](https://scicrunch.org/resolver/SCR_006646)                      <https://bedtools.readthedocs.io/en/latest/content/installation.html>

  Software, algorithm                              HOMER 4.10                                                                                                                      [@bib17]                                                                   RRID:[SCR_010881](https://scicrunch.org/resolver/SCR_010881)                      <http://homer.ucsd.edu/homer/download.html>

  Software, algorithm                              GREAT 3.0.0                                                                                                                     [@bib33]                                                                   RRID:[SCR_005807](https://scicrunch.org/resolver/SCR_005807)                      <http://great.stanford.edu/public/html/>

  Software, algorithm                              Adobe Illustrator CS5                                                                                                           Adobe                                                                      RRID:[SCR_010279](https://scicrunch.org/resolver/SCR_010279)                      

  Software, algorithm                              Adobe Photoshop CS5                                                                                                             Adobe                                                                      RRID:[SCR_014199](https://scicrunch.org/resolver/SCR_014199)                      

  Software, algorithm                              GraphPad Prism v7.05                                                                                                            GraphPad Software, LLC                                                     RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)                      

  Other                                            Novex 16% Tricine Protein Gel                                                                                                   Thermo Fisher Scientific                                                   Cat\# EC66955BOX                                                                  

  Other                                            Novex Tricine SDS Sample Buffer (2X)                                                                                            Thermo Fisher Scientific                                                   Cat\# LC1676                                                                      

  Other                                            Immobilon-PSQ PVDF Membrane                                                                                                     Merck Millipore                                                            Cat\# ISEQ00010                                                                   

  Other                                            Stellaris RNA FISH Hybridisation Buffer                                                                                         LGC Biosearch Technologies                                                 Cat\# SMF-HB1-10                                                                  

  Other                                            Stellaris RNA FISH Wash Buffer A                                                                                                LGC Biosearch Technologies                                                 Cat\# SMF-WA1-60                                                                  

  Other                                            Stellaris RNA FISH Wash Buffer B                                                                                                LGC Biosearch Technologies                                                 Cat\# SMF-WB1-20                                                                  

  Other                                            QuickExtract DNA Extraction Solution                                                                                            Lucigen                                                                    Cat\# QE09050                                                                     

  Other                                            Vectashield Antifade Mounting Medium                                                                                            Vector Laboratories                                                        Cat\# H-1000                                                                      

  Other                                            FastDigest BpiI                                                                                                                 Thermo Fisher Scientific                                                   Cat\# FD1014                                                                      

  Other                                            FastDigest BshTI                                                                                                                Thermo Fisher Scientific                                                   Cat\# FERFD1464                                                                   

  Other                                            FastDigest SalI                                                                                                                 Thermo Fisher Scientific                                                   Cat\# FD0644                                                                      

  Other                                            TRIzol                                                                                                                          Thermo Fisher Scientific                                                   Cat\# 15596018                                                                    

  Other                                            Matrigel                                                                                                                        Corning                                                                    Cat\# 356231                                                                      

  Other                                            GlutaMAX                                                                                                                        Thermo Fisher Scientific                                                   Cat\# 35050061                                                                    

  Other                                            DPBS (without calcium and magnesium)                                                                                            Corning                                                                    Cat\# 45000--434                                                                  

  Other                                            mTeSR1 Complete Kit - GMP                                                                                                       STEMCELL Technologies                                                      Cat\# 85850                                                                       

  Other                                            RPMI 1640 Medium, HEPES                                                                                                         Thermo Fisher Scientific                                                   Cat\# 22400--089                                                                  

  Other                                            DMEM/F12 with L-Glutamine, HEPES                                                                                                Corning                                                                    Cat\# 45000--350                                                                  

  Other                                            Dulbecco's Modified Eagle's Medium                                                                                              Corning                                                                    Cat\# 45000--312                                                                  

  Other                                            HyClone Dulbecco's Modified Eagles Medium                                                                                       Thermo Fisher Scientific                                                   Cat\# SH30081.FS                                                                  

  Other                                            MCDB 131                                                                                                                        Thermo Fisher Scientific                                                   Cat\# 10372--019                                                                  

  Other                                            Opti-MEM Reduced Serum Medium                                                                                                   Thermo Fisher Scientific                                                   Cat\# 31985062                                                                    

  Other                                            Insulin-Transferrin-Selenium-Ethanolamine (ITS-X) (100X)                                                                        Thermo Fisher Scientific                                                   Cat\# 51500--056                                                                  

  Other                                            B-27 Supplement (50X)                                                                                                           Thermo Fisher Scientific                                                   Cat\# 17504044                                                                    

  Other                                            Bovine Albumin Fraction V (7.5%)                                                                                                Thermo Fisher Scientific                                                   Cat\# 15260037                                                                    

  Other                                            Fetal Bovine Serum                                                                                                              Corning                                                                    Cat\# 35011CV                                                                     

  Other                                            Donkey Serum                                                                                                                    Gemini Bio-Products                                                        Cat\# 100-151/500                                                                 

  Other                                            Fatty Acid-Free BSA                                                                                                             Proliant Biologicals                                                       Cat\# 68700                                                                       

  Other                                            Accutase                                                                                                                        eBioscience                                                                Cat\# 00-4555-56                                                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HEK293T cell culture {#s4-1}
--------------------

HEK293T cells (female) were cultured in a humidified incubator at 37°C with 5% CO~2~ using Dulbecco's Modified Eagle Medium (Corning; 4.5 g/L glucose, \[+\] L-glutamine, \[-\] sodium pyruvate) supplemented with 10% fetal bovine serum (FBS; Corning, Cat\# 35011CV). HEK293T cells were purchased from ATCC (Cat\# CRL-3216, RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)) and tested for mycoplasma prior to the experiment.

hESC culture and maintenance {#s4-2}
----------------------------

H1 hESCs (male) were obtained from WiCell (NIHhESC-10--0043, RRID:[CVCL_9771](https://scicrunch.org/resolver/CVCL_9771)) and tested for mycoplasma on a yearly basis. H1 hESCs were grown in feeder-independent conditions on Matrigel-coated dishes (Corning, Cat\# 356231) with mTeSR1 media (STEMCELL Technologies, Cat\# 85850). Propagation was carried out by passing the cells every 3 to 4 days using Accutase (eBioscience, Cat\# 00-4555-56) for enzymatic cell dissociation. hESC research was approved by the University of California, San Diego, Institutional Review Board and Embryonic Stem Cell Research Oversight Committee.

Pancreatic differentiation {#s4-3}
--------------------------

H1 hESCs were differentiated in a monolayer format as previously described ([@bib43]), with minor modifications. Undifferentiated hESCs were seeded into 24-wells at 0.4 × 10^6^ cells/well in 500 µl mTeSR1 medium. The next day the cells were washed in RPMI media (Thermo Fisher Scientific, Cat\# 22400--089) and then differentiated with daily media changes. In addition to GlutaMAX (Thermo Fisher Scientific, Cat\# 35050061), RPMI medium was supplemented with 0.12% (w/v) NaHCO~3~ and 0.2% (Day 0) or 0.5% (Day 1--3) (v/v) FBS (Corning, Cat\# 35011CV). DMEM/F12 medium (Corning, Cat\# 45000--350) was supplemented with 2% (v/v) FBS and 0.2% (w/v) NaHCO~3~, and DMEM High Glucose medium (HyClone, Thermo Fisher Scientific, Cat\# SH30081.FS) was supplemented with 0.5X B-27 supplement (Thermo Fisher Scientific, Cat\# 17504044). Human Activin A, mouse Wnt3a, human KGF, and human Noggin were purchased from R and D Systems (Cat\# 338-AC/CF, Cat\# 1324-WN-010, Cat\# 251 KG, Cat\# 3344 NG-050). Other media components included TGFβ R1 kinase inhibitor IV (EMD Bioscience, Cat\# 616454), KAAD-Cyclopamine (Toronto Research Chemicals, Cat\# K171000), the retinoid analog TTNPB (Sigma Aldrich, Cat\# T3757), the protein kinase C activator TPB (EMD Chemicals, Cat\# 565740), the BMP type one receptor inhibitor LDN-193189 (Stemgent, Cat\# 04--0074), and an inhibitor of the TGF-β type one activin like kinase receptor ALK5, ALK5 inhibitor II (Enzo Life Sciences, Cat\# ALX-270--445).

1.  Stage 1 (DE; collection on day 3):

2.  Day 0: RPMI/FBS, 100 ng/mL Activin A, 25 ng/mL mouse Wnt3a

3.  Day 1--2: RPMI/FBS, 100 ng/mL Activin A

4.  Stage 2 (GT; collection on day 6):

5.  Day 3: DMEM/F12/FBS, 2.5 µM TGFβ R1 kinase inhibitor IV, 50 ng/mL KGF

6.  Day 4--5: DMEM/F12/FBS, 50 ng/mL KGF

7.  Stage 3 (PP1; collection on day 10):

8.  Day 6--9: DMEM/B27, 3 nM TTNPB, 0.25 mM KAAD-Cyclopamine, 50 ng/mL Noggin

9.  Stage 4 (PP2; collection on day 13):

10. Day 10--12: DMEM/B27, 100 nM ALK5 inhibitor II, 100 nM LDN-193189, 500 nM TPB, 50 ng/mL Noggin

11. Stage 5 (endocrine cell stage; collection on day 16):

12. Day 13--15: DMEM/B27, 100 nM ALK5 inhibitor II, 100 nM LDN-193189, 500 nM TPB, 50 ng/mL Noggin

For ribosome profiling experiments, a scalable suspension culture protocol was employed for differentiation of H1 cells to the PP2 stage ([@bib44]). Undifferentiated hESCs were aggregated by preparing a single cell suspension in mTeSR1 media (STEMCELL Technologies; supplemented with 10 µM Y-27632) at 1 × 10^6^ cells/mL and overnight culture in six-well ultra-low attachment plates (Costar) with 5.5 ml per well on an orbital rotator (Innova2000, New Brunswick Scientific) at 100 rpm. The following day, undifferentiated aggregates were washed in MCDB 131 media (Thermo Fisher Scientific, Cat\# 10372--019) and then differentiated using a multistep protocol with daily media changes and continued orbital rotation at either 100 rpm or at 115 rpm from days 8 to 14. In addition to 1% GlutaMAX (Gibco, Thermo Fisher Scientific, Cat\# 35050061) and 10 mM (days 0--10) or 20 mM (days 11--14) glucose, MCDB 131 media was supplemented with 0.5% (days 0--5) or 2% (days 6--14) fatty acid-free BSA (Proliant Biologicals, Cat\# 68700), 1.5 g/L (days 0--5 and days 11--14) or 2.5 g/L (days 6--10) NaHCO~3~ (Sigma-Aldrich), and 0.25 mM ascorbic acid (days 3--10).

Human Activin A, mouse Wnt3a, and human KGF were purchased from R and D Systems (Cat\# 338-AC/CF, Cat\# 1324-WN-010, Cat\# 251 KG). Other media components included Insulin-Transferrin-Selenium-Ethanolamine (ITS-X; Thermo Fisher Scientific, Cat\# 51500--056; days 6--10), retinoic acid (RA) (Sigma-Aldrich, Cat\# R2625), the sonic hedgehog pathway inhibitor SANT-1 (Sigma-Aldrich, Cat\# S4572), the protein kinase C activator TPB (EMD Chemicals, Cat\# 565740), the BMP type one receptor inhibitor LDN-193189 (Stemgent, Cat\# 04--0074), and the TGFβ type one activin like kinase receptor ALK5 inhibitor, ALK5 inhibitor II (Enzo Life Sciences, Cat\# ALX-270--445).

1.  Stage 1 (DE; collection on day 3):

2.  Day 0: MCDB 131, 100 ng/mL Activin, 25 ng/mL mouse Wnt3a

3.  Day 1--2: MCDB 131, 100 ng/mL Activin A

4.  Stage 2 (GT; collection on day 6):

5.  Day 3 -- Day 5: MCDB 131, 50 ng/mL KGF

6.  Stage 3 (PP1; collection on day 8)

7.  Day 6 -- Day 7: MCDB 131, 50 ng/mL KGF, 0.25 µM SANT-1, 1 µM RA 100 nM LDN-193189, 200 nM TPB

8.  Stage 4 (PP2; collection on day 11):

9.  Day 8 -- Day 10: MCDB 131, 2 ng/mL KGF, 0.25 µM SANT-1, 0.1 µM RA, 200 nM LDN-193189, 100 nM TPB

CRISPR/Cas9-mediated lncRNA knockout {#s4-4}
------------------------------------

To generate clonal lncRNA knockout hESC lines, combinations of pSpCas9(BB)−2A-Puro plasmid pairs (Addgene plasmid \#62988, RRID:[Addgene_62988](https://scicrunch.org/resolver/Addgene_62988), gift from Feng Zhang) expressing Cas9 and single sgRNAs targeting upstream and downstream regions of the lncRNA promoter/locus were co-transfected into 1.5 × 10^6^ H1 hESCs using the Human Stem Cell Nucleofector Kit 2 (Lonza) and the Amaxa Nucleofector II (Lonza). 24 hr after plating into Matrigel-coated six-well plates, nucleofected cells were selected with puromycin (1 µg/mL mTeSR1 media) for 2--3 consecutive days. Individual colonies that emerged within 7 days after transfection were subsequently transferred manually into 96-well plates for expansion. Genomic DNA for PCR genotyping with GoTaq Green Mastermix (Promega) and Sanger sequencing was then extracted using QuickExtract DNA Extraction Solution (Lucigen).

To generate sORF frameshift mutations, sgRNA sequences targeting the N-terminal region of the predicted small peptides were inserted into pSpCas9(BB)−2A-GFP (Addgene plasmid \#48138, RRID:[Addgene_48138](https://scicrunch.org/resolver/Addgene_48138), gift from Feng Zhang) via its BpiI cloning sites. 3 µg of the resulting plasmids were then transfected into 500,000 H1 cells plated into Matrigel-coated six-wells the day prior, using XtremeGene 9 Transfection Reagent (Sigma-Aldrich) according to the manufacturer's instructions. 24 hr post-transfection, 10,000 GFP^+^ cells were sorted on an Influx Cell Sorter (BD Biosciences) into Matrigel-coated six-wells containing 1 mL mTeSR1 media supplemented with 10 µM ROCK inhibitor and 1X penicillin/streptomycin. Seven days after sorting, emerging colonies were hand-picked and transferred into 96-well plates for genotyping. Frameshifts inside the targeted sORFs were confirmed by PCR-amplification of the sORF sequence with GoTaq Green Mastermix (Promega, Cat\# M7123) and subsequent subcloning the PCR products into pCR2.1 (Thermo Fisher Scientific). For each hESC clone, at least six pCR2.1 clones were Sanger sequenced. Oligonucleotide sequences for sgRNA cloning are provided in [Figure 4---source data 2A](#fig4sdata2){ref-type="supplementary-material"}.

PCR genotyping of CRISPR clones {#s4-5}
-------------------------------

Four days after transfer of single cell-derived clones into 96-wells, cell culture supernatants containing dead cells were collected from each well prior to the daily media change. Cell debris was then pelleted and used for gDNA extraction with 10--20 µl QuickExtract DNA Extraction Solution (Lucigen, Cat\# QE09050) according to the manufacturer's instructions. 1 µl DNA was then PCR-amplified with GoTaq Green Mastermix (Promega, Cat\# M7123) and locus-specific primers that anneal either within or outside of the excised genomic DNA. PCR products generated with 'inside' primers were visualized on a 2% agarose gel, PCR bands generated with primers flanking the deletion were gel-purified and submitted for Sanger sequencing (see [Figure 4---source data 2B](#fig4sdata2){ref-type="supplementary-material"} for genotyping and sequencing primers).

For genotyping of sORF frameshift clones, PCR amplicons designed to encompass the Cas9 cut site were amplified and Sanger sequenced ([Figure 4---source data 2B](#fig4sdata2){ref-type="supplementary-material"}). If out-of-frame indels were apparent in the sequencing chromatogram, the sequenced PCR product was ligated into pCR2.1-TOPO via TOPO-TA cloning. A minimum of six clones were Sanger sequenced in order to determine the genotype at both alleles with high confidence.

Generation of sORF translation reporter plasmids {#s4-6}
------------------------------------------------

The four lncRNAs tested were PCR-amplified with KOD Xtreme DNA Hotstart Polymerase (Millipore) from their 5' end up until the last codon of the sORF to be tested, omitting its stop codon (primer sequences are listed in [Figure 4---source data 2D](#fig4sdata2){ref-type="supplementary-material"}). cDNA was used as PCR template for *LINC00261* and *LHFPL3-AS2; RP11-834C11.4*, and *MIR7-3HG* were amplified from a gBlock synthetic gene fragment (Integrated DNA Technologies; see [Figure 4---source data 2F](#fig4sdata2){ref-type="supplementary-material"}). The GFP coding sequence (without start codon; amplified from pRRLSIN.cPPT.PGK-GFP.WPRE; RRID:[Addgene_12252](https://scicrunch.org/resolver/Addgene_12252)) was then fused in-frame to the sORF via overlap extension PCR. The resulting fusion product was cloned into pRRLSIN.cPPT.PGK-GFP.WPRE (Addgene plasmid \#12252, gift from Didier Trono) via BshTI and SalI restriction sites included in the PCR primers. Due to the 3'-location of sORF7 within *LINC00261*, not the entire *LINC00261* cDNA was amplified but only 65 bp preceding sORF7.

To create the *RP11-834C11.4*-sORF-1XFLAG reporter construct in an analogous way, a gBlock synthetic gene fragment encompassing the FLAG-tagged sORF served as PCR template ([Figure 4---source data 2F](#fig4sdata2){ref-type="supplementary-material"}). The resulting PCR product was cloned into pRRLSIN.cPPT.PGK-GFP.WPRE via BshTI and SalI restriction sites.

Generation of *LINC00261* wild type and ΔATG^sORF1-7^ expression plasmids {#s4-7}
-------------------------------------------------------------------------

The *LINC00261* wild type cDNA was PCR-amplified from pENTR/D-TOPO-*LINC00261* (gift from Leo Kurian) with KOD Xtreme DNA Hotstart Polymerase (Millipore, Cat\# 71975). The resulting PCR product was inserted into pRRLSIN.cPPT.PGK-GFP.WPRE via its appended BshTI/SalI cloning sites. Full-length *LINC00261* ΔATG^sORF1-7^ was assembled through overlap extension PCR from the following three fragments and subsequently cloned into pRRLSIN.cPPT.PGK-GFP.WPRE via appended BshTI/SalI cloning sites: (i) a 1,248 bp PCR product amplified from a synthetic gene construct (Genewiz; see [Figure 4---source data 2F](#fig4sdata2){ref-type="supplementary-material"} for sequence) in which the ATG start codons of sORFs 1--6 had been mutated (ATG → AAG/ATT/ AGG/AAG/ ATA/AGG), and (ii-iii) 3,111 bp/610 bp PCR fragments (amplified from the *LINC00261* cDNA) in which the sORF7 start codon was mutated (ATG → AAG). The obtained plasmids were sequence-verified by Sanger sequencing.

Immunofluorescence staining {#s4-8}
---------------------------

H1 hESC-derived cells grown as monolayer on Matrigel-coated coverslips were washed twice with PBS and then fixed with 4% paraformaldehyde in PBS for 30 min at room temperature. Following three washes in PBS, samples on coverslips were permeabilized and blocked with Permeabilization/Blocking Buffer (0.15% (v/v) Triton X-100% and 1% normal donkey serum in PBS) for 1 hr at room temperature. Primary and secondary antibodies were diluted in Permeabilization/Blocking Buffer. Sections were incubated overnight at 4°C with primary antibodies, and then secondary antibodies for 30 min at room temperature. The following primary antibodies were used: rabbit anti-OCT4 (Cell Signaling Technology, Cat\# 2890, RRID:[AB_2167725](https://scicrunch.org/resolver/AB_2167725), 1:500), goat anti-SOX17 (Santa Cruz Biotechnology, Cat\# AF1924, RRID:[AB_355060](https://scicrunch.org/resolver/AB_355060), 1:250), goat anti-FOXA2 (Santa Cruz Biotechnology, Cat\# sc-6554, RRID:[AB_2262810](https://scicrunch.org/resolver/AB_2262810), 1:250), goat anti-GATA6 (Santa Cruz Biotechnology, Cat\# sc-9055, RRID:[AB_2108768](https://scicrunch.org/resolver/AB_2108768), 1:50), guinea pig anti-insulin (Dako, Cat\# A0564, RRID:[AB_10013624](https://scicrunch.org/resolver/AB_10013624)). Secondary antibodies (1:1000) were Cy3- or Alexafluor488-conjugated antibodies raised in donkey against guinea pig, rabbit or goat (Jackson ImmunoResearch Laboratories, Cat\# 706-545-148, RRID:[AB_2340472](https://scicrunch.org/resolver/AB_2340472), Cat\# 711-545-152, RRID:[AB_2313584](https://scicrunch.org/resolver/AB_2313584), Cat\# 705-165-147, RRID:[AB_2307351](https://scicrunch.org/resolver/AB_2307351)). Images were acquired on a Zeiss Axio-Observer-Z1 microscope with a Zeiss AxioCam digital camera, and figures prepared with Adobe Photoshop/Illustrator CS5.

Flow cytometry analysis {#s4-9}
-----------------------

For intracellular flow cytometry, single cells were washed three times in FACS buffer (0.1% (w/v) BSA (Thermo Fisher Scientific in PBS) and then fixed and permeabilized with Cytofix/Cytoperm Fixation/Permeabilization Solution (BD Biosciences) for 20 min at 4°C, followed by two washes in BD Perm/Wash Buffer. Cells were next incubated with either PE-conjugated anti-SOX17 antibody (BD Biosciences; Cat\# 561591, RRID:[AB_10717121](https://scicrunch.org/resolver/AB_10717121)), or PE-conjugated anti-INS antibody (Cell Signaling Technology, Cat\# 8508S, RRID:[AB_11179076](https://scicrunch.org/resolver/AB_11179076)) in 50 µl BD Perm/Wash Buffer for 60 min at 4°C. Following three washes in BD Perm/Wash Buffer, cells were analyzed on a FACSCanto II (BD Biosciences) cytometer.

Insulin content measurements {#s4-10}
----------------------------

To measure total insulin content of endocrine cell stage control and lncRNA KO cells, adherent cultures were enzymatically detached from a 24-well at day 16 of differentiation. Upon quenching with FACS buffer (0.1% (w/v) BSA (Thermo Fisher Scientific in PBS), the cells were pelleted and extracted over night at 4°C in 100 µl acid-ethanol (2% HCl in 80% ethanol). Insulin was measured by Insulin ELISA (Alpco, Cat\# 80-INSHU-E10.1) and normalized to total protein, as quantified with a BCA protein assay (Thermo Fisher Scientific, Cat\# 23227).

Quantitative reverse transcription PCR (qRT-PCR) {#s4-11}
------------------------------------------------

Total RNA was isolated from hESC-derived cells and HEK293T cells using either TRIzol (Thermo Fisher Scientific, Cat\# [15596018](https://www.thermofisher.com/order/catalog/product/15596018)) or the RNAeasy Mini Kit (Qiagen, Cat\# [15596018](https://www.thermofisher.com/order/catalog/product/15596018)), respectively. Upon removal of genomic DNA (TURBO DNA-free Kit, Thermo Fisher Scientific, Cat\# AM1907 or RNase-free DNase Set, Qiagen, Cat\# 79254) cDNA was synthesized using the iScript cDNA Synthesis Kit (Bio-Rad, Cat\# 1708890). PCR reactions were run in triplicate with 6.25--12.5 ng cDNA per reaction using the CFX96 Real-Time PCR Detection System (BioRad). TATA-binding protein (TBP) was used as endogenous control to calculate relative gene expression using the ΔΔCt method. Primer sequences are provided in [Figure 4---source data 2C](#fig4sdata2){ref-type="supplementary-material"}.

Transient transfection of HEK293T cells with polyethylenimine (PEI) {#s4-12}
-------------------------------------------------------------------

Two hours prior to transfection, fresh pre-warmed DMEM medium (Corning, Cat\# 45000--312) was added to each well. Transfection mix was prepared by combining PEI (Polysciences Cat\# 23966--1) and plasmid DNA (4:1 ratio; 4 µg PEI per 1 µg DNA) in Opti-MEM Reduced Serum Medium (Thermo Fisher Scientific, Cat\# 31985062) followed by brief vortexing. After five minutes, the transfection complex was added dropwise to the cells.

Lentivirus preparation and ectopic *LINC00261* expression {#s4-13}
---------------------------------------------------------

Lentiviral particles were prepared by co-transfecting HEK293T cells (using PEI) with the pCMVR8.74/pMD2.G helper plasmids (Addgene plasmids \#22036/12259, RRID:[Addgene_22036](https://scicrunch.org/resolver/Addgene_22036) and RRID:[Addgene_12259](https://scicrunch.org/resolver/Addgene_12259), gift from Didier Trono) and with pRRLSIN.cPPT.PGK-GFP.WPRE transfer plasmid (RRID:[Addgene_12252](https://scicrunch.org/resolver/Addgene_12252)), in which the GFP ORF had been replaced with the 4.9 kb *LINC00261* cDNA. Virus-containing supernatant was collected for two consecutive days and concentrated by ultracentrifugation for 2 hr at 19,400 rpm using an Optima L-80 XP Ultracentrifuge (Beckman Coulter).

To express *LINC00261* (wild type) and *LINC00261* (ΔATG^sORF1-7^) in HEK293T cells, the cells were plated in 6-well plates and transduced with lentivirus the following day. Two days post infection, the cells were passaged for RNA half-life measurements.

*LINC00261* RNA half-life measurement {#s4-14}
-------------------------------------

HEK293T cells transduced with either *LINC00261* (wild type) or *LINC00261* (ΔATG^sORF1-7^) lentivirus were seeded in six 24-wells. 48 hr after plating, cells from one well were collected for RNA isolation as the '0 hr' time point. To the remaining five wells, 100 µl growth media supplemented with 10 µg/ml actinomycin D (Sigma-Aldrich Cat\# A9415) were added to inhibit transcription. At 2, 4, 6, 8, and 9 hr following actinomycin D addition, samples were collected for RNA isolation. Total RNA was then reverse transcribed and analyzed by qPCR, where the abundance of each time point was calculated relative to the abundance at the 0 hr time point (ΔCt). The half-life was then determined by non-linear regression (One phase decay; GraphPad Prism).

Single molecule RNA fluorescence in situ hybridization (smRNA FISH) {#s4-15}
-------------------------------------------------------------------

H1-derived PP2 stage cells (control and *LINC00261* KO) were cultured on Matrigel-coated 12 mm diameter coverslips in a 24-well plate. Following 10 min fixation in 1 mL Fixation Buffer (3.7% (v/v) formaldehyde in PBS) at room temperature, the cells were washed twice in PBS and subsequently permeabilized in 70% (v/v) ethanol for one hour at 4°C. Following a five minute wash in Stellaris RNA FISH Wash Buffer A (LGC Biosearch Technologies, Cat\# SMF-WA1-60; 1:5 diluted concentrate, with 10% (v/v) formamide added), the coverslips were incubated in a humidified chamber at 37°C for 14 hr with probes diluted in Stellaris RNA FISH Hybridisation Buffer (LGC Biosearch Technologies, Cat\# SMF-HB1-10; with 10% (v/v) formamide added) to 125 nM. After a 30 min wash at 37°C in Wash Buffer A, the cells were counter-stained with Hoechst 33342 (Thermo Fisher Scientific) for 15 min and washed in RNA FISH Wash Buffer B (LGC Biosearch Technologies, Cat\# SMF-WB1-20) for 5 min at room temperature. The coverslips were mounted in Vectashield Mounting Medium (Vector Laboratories, Cat\# H-1000) and imaged on a UltraView Vox Spinning Disk confocal microscope (PerkinElmer) using a 100X oil objective.

In vitro transcription/translation of lncRNAs {#s4-16}
---------------------------------------------

Synthetic gene constructs containing complete transcript isoforms (including the predicted 5' and 3' UTR) of four translated lncRNAs (*RP11-834C11.4*, *LINC00261*, *MIR7-3HG*, and *LHFPL3-AS2*) were produced by Genewiz (constructs available upon request). Microproteins were translated in vitro from 0.5 µg linearized plasmid DNA using the TnT Coupled Wheat Germ Extract system (Promega; Cat\# L4140) in the presence of 10 mCi/mL \[^35^S\]-methionine (Hartmann Analytic) according to manufacturer's instructions. 5 µL lysate was denatured for 2 min at 85°C in 9.6 µL Novex Tricine SDS Sample Buffer (2X) (Thermo Fisher Scientific; Cat\# LC1676) and 1.4 µL DTT (500 mM). Proteins were separated on 16% Tricine gels (Thermo Fisher Scientific; Cat\# EC66955BOX) for 1 hr at 50 V followed by 3.5 hr at 100 V and blotted on PVDF-membranes (Immobilon-PSQ Membrane, Merck Millipore; Cat\# ISEQ00010). Incorporation of \[^35^S\]-methionine into newly synthesized proteins enabled the detection of translation products by phosphor imaging (exposure time of 1 day).

In vivo translation assays {#s4-17}
--------------------------

Reporter plasmids were transfected into HEK293T cells using PEI, and 36 hr post transfection live cells were imaged on an EVOS Cell Imaging System (Thermo Fisher Scientific) equipped with a 20X objective. Additional constructs were generated that served as negative controls (no GFP fluorescence): 1) a *LINC00261*-sORF3-GFP construct with a single 'T' insertion inside sORF3, causing a frame-shift, 2) a *LINC00261*-sORF2-GFP construct with a stop codon preceding the GFP coding sequence, and 3) a *LINC00261*-sORF1-GFP construct with a frame-shift mutation within the GFP coding sequence.

Stranded mRNA-seq library preparation for lncRNA KOs {#s4-18}
----------------------------------------------------

Total RNA from PP2 cells differentiated with the [@bib43] protocol was isolated and DNase-treated using either TRIzol (Thermo Fisher Scientific), or the RNAeasy Mini kit (Qiagen) according to the manufacturer's instructions. RNA integrity (RIN \> 8) was verified on the Agilent 2200 TapeStation (Agilent Technologies), and 400 ng RNA was used for multiplex library preparation with the KAPA mRNA HyperPrep Kit (Roche; Cat\# KK8581). All libraries were evaluated on TapeStation High Sensitivity DNA ScreenTapes (Agilent Technologies; Cat\# 5067--5584) and with the Qubit dsDNA High Sensitivity (Life Technologies; Cat\# Q10212) assays for size distribution and concentration prior to pooling the multiplexed libraries for single-end 1 × 51 nt or 1 × 75 sequencing on the HiSeq 2500 or HiSeq 4000 System (Illumina). Libraries were sequenced to a depth of \> 20M uniquely aligned reads.

Cell fractionation and ribo-minus RNA-seq {#s4-19}
-----------------------------------------

H1 hESCs were differentiated to the PP2 stage with the [@bib43] protocol, then nuclear and cytosolic RNA was isolated with the Paris Kit (Thermo Fisher Scientific). Unfractionated total RNA was set aside as a control. All samples were DNaseI-treated prior to further processing (TURBO DNA-free Kit; Thermo Fisher Scientific). rRNA-depleted total RNA-seq libraries were prepared with TruSeq Stranded Total RNA Library Prep Gold (Illumina; Cat\# 2002059), and sequencing was performed on a HiSeq4000 instrument.

Alignment of lncRNA KO mRNA-seq samples and processing for gene expression analysis {#s4-20}
-----------------------------------------------------------------------------------

Using the Spliced Transcripts Alignment to a Reference (STAR) aligner (STAR 2.5.3b; [@bib15]), sequence reads were mapped to the human genome (hg38/GRCh38) with the Ensembl 87 annotations in 2-pass mapping mode, allowing for up to six mismatches. Cufflinks (part of the Cufflinks version 2.2.1 suite; [@bib45]; [@bib57]), was then used to quantify the abundance of each transcript cataloged in the Ensembl 87 annotations in reads per kilobase per million mapped reads (RPKM). For plotting expression values, a pseudocount of 1 was added to all RPKM values prior to log~2~-transformation.

Genes with RPKM ≥ 1 across two replicates were deemed expressed. Differential gene expression was tested using the DESeq2 v1.10.1 Bioconductor package ([@bib28]) with default parameters. Input count files for DESeq2 were created with htseq-count from the HTSeq Python library ([@bib3]). Genes with a \> 2 fold change and an adjusted p-value of \<0.01 were considered differentially expressed.

The chromosomal localization of genes differentially expressed upon *LINC00261* KO was visualized with the RCircos package in R (<https://cran.r-project.org/web/packages/RCircos/index.html>).

LncRNA classifications {#s4-21}
----------------------

The following transcript biotypes were grouped into the 'lncRNA' classification: 3' overlapping ncrna, antisense, bidirectional promoter lncRNA, lincRNA, macro lncRNA, non coding, processed transcript, sense intronic, sense overlapping, TEC.

LncRNAs with ≥1 RPKM during all differentiation stages of CyT49 hESCs (ES, DE, FG, GT, PP1, PP2) were categorized as constitutively expressed ('constitutive'), whereas lncRNAs with \<1 RPKM throughout differentiation were considered 'never expressed'. LncRNAs expressed in at least one of the stages (but not in all five stages) were referred to as dynamically expressed ('dynamic'). Furtheremore, for each lncRNA, its maximum RPKM value was determined across 38 tissues/cell types (see 'Gene-gene correlations and GO enrichment' section below). Log~2~-transformed maximum expression values (RPKM + pseudocount of 1) were graphed as boxplots for different gene sets using the ggplot2 R package (<https://cran.r-project.org/web/packages/ggplot2/index.html>).

To determine the subcellular localization of lncRNAs, first all lncRNAs expressed in the nuclear and/or cytosolic RNA fraction (RPKM ≥ 1 in two biological replicates) of H1-derived PP2 stage cells were selected. Among these expressed lncRNAs, those with ≥ 1 RPKM~cytosol~ and \< 1 RPKM~nucleus~ were classified as 'cytosol enriched'. Conversely, lncRNAs with \< 1 RPKM~cytosol~ and ≥ 1 RPKM~nucleus~ were termed 'nucleus enriched'. LncRNAs expressed in both fractions (≥1 RPKM~cytosol~ and ≥ 1 RPKM~nucleus~) were tagged with 'both'.

Assignment of lncRNAs to their nearest coding gene using GREAT {#s4-22}
--------------------------------------------------------------

GREAT (Genomic Regions Enrichment of Annotations Tool 3.0.0; [@bib33]) was run with the 'Single nearest gene' within 1000 kb option to assign the nearest coding genes to the following sets of lncRNAs: i) DE-transcribed lncRNAs, ii) PP2-transcribed lncRNAs that are not transcribed at the DE stage (non-transcribed control set for i)), iii) PP2-transcribed lncRNAs, and iv) lncRNAs transcribed at the DE stage but not transcribed in PP2 cells (non-transcribed control set for iii)). The log~2~-transformed RPKM values of the lncRNA-associated coding genes were then graphed as boxplots using ggplot2. The corresponding absolute coding-to-lncRNA inter-gene distances were visualized as cumulative frequency plots.

Gene-gene correlations and GO enrichment {#s4-23}
----------------------------------------

Pearson correlations were calculated among all genes across a catalog of 38 tissues/cell types derived from all three germ layers (16 Illumina BodyMap 2.0 tissues, other publicly available data sets (see 'Data sources' below), and EndoC-βH1 RNA-seq data generated in our lab). Scatter plots of the log~2~-transformed RPKM values for lncRNAs/neighboring TFs and histograms of the Pearson correlation coefficients were plotted in R using ggplot2.

Spearman correlations were calculated to test for expression coregulation among all genes expressed (RPKM ≥ 1) in a minimum of ten out of 38 tissues. The resulting correlation matrix was then used to calculate the Euclidean distance followed by hierarchical clustering. The resulting heatmap was subdivided into ten clusters. Cluster visualization was done using heatmap.3 (<https://raw.githubusercontent.com/obigriffith/biostar-tutorials/master/Heatmaps/heatmap.3.R>) from gplots v3.0.1 (<http://cran.r-project.org/web/packages/gplots/index.html>). GO enrichment ([@bib6]; [@bib56]) and KEGG pathway ([@bib20]) analyses to assign functional annotation to all ten clusters were performed with gProfiler v0.6.4 ([@bib42]) using g:Profiler archive revision 1741 (Ensembl 90, Ensembl Genomes 38).

Alignment and processing of ChIP-seq samples {#s4-24}
--------------------------------------------

All sequence reads were filtered to include only those passing the standard Illumina quality filter, and then aligned to the *Homo sapiens* reference genome (hg38/GRCh38) using Bowtie version 1.1.1 ([@bib23]). The following parameters were used to select only uniquely aligning reads with a maximum of two mismatches:$$- k1 - m1 - l50 - n2 - best - strata$$

SAMtools ([@bib25]) was then used to filter reads with a MAPQ score less than 30 and to remove duplicate reads. Finally, replicate ChIP-seq and input BAM files were merged and sorted. The HOMER makeUCSCfile function ([@bib17]) was used to create a bedGraph formatted file for viewing in the UCSC Genome Browser.

Ribosome profiling and matching RNA-seq {#s4-25}
---------------------------------------

Ribosome profiling was performed on PP2 cells obtained from six independent differentiations of H1 hESCs with the [@bib44] protocol, yielding an average of 89% PDX1-positive cells. Ribosome footprinting and sequencing library preparation was done with the TruSeq Ribo Profile (Mammalian) Library Prep Kit (Illumina, Cat\# RPYSC12116, currently out of production) according to the TruSeq Ribo Profile (Mammalian) Reference Guide (version August 2016). In short, 50 mg of PP2 aggregates were washed twice with cold PBS and lysed for 10 min on ice in 1 mL lysis buffer (1 × TruSeq Ribo Profile mammalian polysome buffer, 1% Triton X-100, 0.1% NP-40, 1 mM dithiothreitol, 10 U ml^−1^ DNase I, cycloheximide (0.1 mg/ml) and nuclease-free H~2~O). Per sample, 400 μL of lysate was further processed according to manufacturer\'s instructions. Final library size distributions were checked on the Bioanalyzer 2100 using a High Sensitivity DNA assay (Agilent Technologies), multiplexed and sequenced on an Illumina HiSeq 4000 producing single end 1 × 51 nt reads. Ribo-seq libraries were sequenced to an average depth of 85M reads.

Total RNA was isolated using TRIzol Reagent (Thermo Fisher Scientific) from the exact same cell cultures processed for ribosome profiling (10% of the total number of cells). Total RNA was DNase treated and purified using the RNA Clean and Concentrator−25 kit (Zymo Research). RIN scores (RIN = 10 for all six samples) were measured on a BioAnalyzer 2100 using the RNA 6000 Nano assay (Agilent Technologies). Poly(A)-purified mRNA-seq library preparation was performed according to the TruSeq Stranded mRNA Reference Guide (Illumina), using 500 ng of total RNA as input. Libraries were multiplexed and sequenced on an Illumina HiSeq 4000 producing paired-end 2 × 101 nt reads.

Alignment of Ribo-seq and matched mRNA-seq samples {#s4-26}
--------------------------------------------------

Prior to mapping, ribosome-profiling reads were clipped for residual adapter sequences and filtered for mitochondrial, ribosomal RNA and tRNA sequences ([Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). Next, all mRNA and ribosome profiling data were mapped to the Ensembl 87 transcriptome annotation of the human genome hg38 assembly using STAR 2.5.2b ([@bib15]) in 2-pass mapping mode. To avoid mRNA-seq mapping biases due to read length, the 2 × 101 nt mRNA-seq reads were next trimmed to 29-mers, and those mRNA reads were processed and mapped with the exact same settings as the ribosome profiling data. For the mapping of 2 × 101 nt RNA-seq reads six mismatches per read were allowed (default is 10), whereas two mismatches were permitted for the Ribo-seq and trimmed mRNA-seq reads. To account for variable ribosome footprint lengths, the search start point of the read was defined using the option `--seedSearchStartLmaxOverLread`, which was set to 0.5 (half the read, independent of ribosome footprint length). Furthermore, `--outFilterMultimapNmax` was set to 20 and `--outSAMmultNmax` to 1, which prevents the reporting of multimapping reads.

Detecting actively translated reading frames {#s4-27}
--------------------------------------------

Canonical ORF detection using ribosome profiling data was performed with RiboTaper v1.3 ([@bib10]) with standard settings. For each sample, we selected only the ribosome footprint lengths for which at least 70% of the reads matched the primary ORF in a meta-gene analysis. Following the standard configuration of RiboTaper, we required ORFs to have a minimum length of 8aa, evidence from uniquely mapping reads and at least 21 P-sites. The final list of translation events was stringently filtered requiring the translated gene to have an average RNA RPKM ≥ 1 and to be detected as translated in all six profiled samples. Furthermore, we required the exact ORF to be detected independently in at least 4 out of 6 samples.

Translational efficiency estimates {#s4-28}
----------------------------------

Translational efficiency (TE) estimations were calculated as the ratio of Ribo-seq over mRNA-seq DESeq2 normalized counts, yielding independent gene-specific TEs for each of the six individual replicate differentiations. For this, mRNA-seq and Ribo-seq based expression quantification was calculated for (annotated and newly detected) coding sequences (CDSs/ORFs) only, using RNA reads trimmed to footprint sizes as described above.

Data sources {#s4-29}
------------

The following datasets used in this study were downloaded from the GEO and ArrayExpress repositories:

RNA-seq: Illumina BodyMap 2.0 expression data from 16 human tissues (GSE30611); polyA mRNA RNA-seq from BE2C (GSE93448), GM12878 (GSE33480), 293T (GSE34995), HeLa (GSE33480), HepG2 (GSE90322), HUVEC (GSE33480), Jurkat (GSE93435), K562 (GSE33480), MiaPaCa-2 (GSE43770), Panc1 (GSE93450), PFSK-1 (GSE93451), U-87 MG (GSE90176); CyT49 hESC/DE/GT/PP1/PP2/CD142+ progenitors/CD200+ polyhormonal cells/in vivo matured endocrine cells/pancreatic islets (E-MTAB-1086).

ChIP-seq: H3K4me3/H3K27me3 in CyT49 hESC/DE/GT/PP1/PP2 (E-MTAB-1086).

Statistical analyses {#s4-30}
--------------------

Statistical analyses were performed using Microsoft Excel, GraphPad Prism (7.05), and R (v.3.5.0).Statistical parameters such as the value of n, mean, standard deviation (S.D.), standard error of the mean (S.E.M.), significance level (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 and \*\*\*\*p\<0.0001), and the statistical tests used are reported in the figures and figure legends. The ''n'' refers to the number of independent pancreatic differentiation experiments analyzed (biological replicates), or the number of genes/transcripts and sORFs detected.

Statistically significant gene expression changes were determined with DESeq2.
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All mRNA-seq and Ribo-seq datasets generated for this study have been deposited at GEO under the accession number GSE144682.

The following dataset was generated:

GaertnerBvan HeeschSSchneider-LunitzVSchulzJFWitteFBlachutSNguyenSWongRMattaIHubnerNSanderM2020The role of long noncoding RNAs during pancreas developmentNCBI Gene Expression OmnibusGSE144682

The following previously published datasets were used:

KhrebtukovaI2011Illumina BodyMap 2.0NCBI Gene Expression OmnibusGSE30611

ENCODE project consortium2012RNA-seq from ENCODE/CaltechNCBI Gene Expression OmnibusGSE33480

ENCODE Project Consortium2012polyA mRNA RNA-seq from BE2C (ENCSR000BYK)NCBI Gene Expression OmnibusGSE93448

HuelgaSCVuAQArnoldJDLiangTYLiuPPYanBYDonohueJPShiueLHoonSBrennerSAresMYeoGW2012Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins (RNA-Seq)NCBI Gene Expression OmnibusGSE34995

ENCODE Project Consortium2016polyA mRNA RNA-seq from HepG2 (ENCSR329MHM)NCBI Gene Expression OmnibusGSE90322

ENCODE Project Consortium2017polyA mRNA RNA-seq from Jurkat clone E61 (ENCSR000BXX)NCBI Gene Expression OmnibusGSE93435

ShermanMHYuRTEngleDDDingNAtkinsARTiriacHCollissonEAConnorFVan DykeTKozlovSMartinPTsengTWDawsonDWDonahueTRMasamuneAShimosegawaTApteMVWilsonJSNgBLauSLGuntonJEWahlGMHunterTDrebinJAO\'DwyerPJLiddleCTuvesonDADownesMEvansRM2014Vitamin d receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapyNCBI Gene Expression OmnibusGSE43770

ENCODE Project Consortium2017polyA mRNA RNA-seq from Panc1 (ENCSR000BYM)NCBI Gene Expression OmnibusGSE93450

ENCODE Project Consortium2017polyA mRNA RNA-seq from PFSK-1 (ENCSR000BYN)NCBI Gene Expression OmnibusGSE93451

ENCODE Project Consortium2016polyA mRNA RNA-seq from U-87 MG (ENCSR000BYO)NCBI Gene Expression OmnibusGSE90176

XieREverettLJLimHWPatelNASchugJKroonEKellyOGWangAD\'AmourKARobinsAJWonKJKaestnerKHSanderM2013ChIP-seq and RNA-seq of coding RNA of the progression of human embryonic stem cells to beta cells to characterize the epigenetic programs that underlie pancreas differentiationArrayExpressE-MTAB-1086
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Reviewing Editor

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The study nicely documents the existence of many cytoplasmic lncRNAs in the vicinity of lineage-determining transcription factors. Extensive functional analysis of one such lncRNA -- *LINC00261* -- demonstrates its importance in the differentiation of human embryonic stem cells into pancreatic endocrine cells. Interestingly, the function of *LINC00261* is independent of its potential microproteins and regulation of the neighboring transcription factor FOXA2. These studies highlight the complexity of lncRNA regulation of developmental processes.

**Decision letter after peer review:**

Thank you for submitting your article \"A microprotein-independent role for highly translated lncRNA LINC00261 in pancreatic endocrine cell development\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Didier Stainier as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in *eLife* but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data.

Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in *eLife*, either of which would be linked to the original paper.

Summary:

This is a comprehensive study of mapping lncRNA expression during hESC differentiation towards the pancreatic endocrine cell lineage, combined with an evaluation of whether small open reading frames within each lncRNA could be expressed and have functional effects. Gaertner and co-workers map cytoplasm-located lncRNAS associated with translating ribosomes using the RiboSeq method and observed a comparatively frequent prediction of small open reading frames (smORFs) in these lncRNAs. Many of these smORFs could be translated in vitro using TnT assays. To investigate these smORF containing lncRNAs further, 10 were selected based on expression pattern and genomic context, and homozygous knock-out hESC lines were generated. One of these, LINC00261, was investigated in depth and each of its 7 smORFs were deleted in individual hESC lines. Although full-length LINC00261 was shown to have a role in INS+ cell differentiation, individual deletion of its smORFs did not affect INS+ cell differentiation. Simultaneous deletion of all 7 ORFs did not affect transcript stability; however functional activity of the mutated lncRNA wasn\'t tested. The authors conclude that the action of LINC00261 on hESC differentiation to INS+ cells is independent of the harbored smORFs.

Essential revisions:

Although this is an interesting study with novel information regarding lncRNAs in islet cell differentiation, the authors make claims throughout the manuscript that are not supported by their data, therefore their conclusions should be limited to what they actually show. The majority of these issues can be corrected by careful editing, but they also somewhat diminish the impact of the study. In addition, the manuscript text should be carefully checked for overstatements. For example, in the first paragraph of the Results section, the authors state that majority of lncRNAs showed dynamic expression patterns. These are not a majority as they represent 37%.

Primary concern: If the authors wish to claim that the linc00261 function is independent of the smORFs ability to be translated, then they must present data on differentiation capability cells having the simultaneously mutated smORFs, in addition to the linc00261 transcript stability data. In the current version, they have not probed the functional effects of mutating all the smORFs, which could be redundant. However, if they are not able to produce this data, then they will have to change the title and conclusions of the manuscript to reflect what they actually show.

As for their data on the smORFs (Figure 2), they have shown that the smORF-coding nucleotides bind to the ribosome and generate the classic 3-letter foot-print indicative of translation. They have shown that RNAs corresponding to the smORFs can undergo forced expression with translation into fusion protein using high expression levels in HEK293 cells. However, showing that the smORFs associate with the ribosome or can forcefully be translated, does not demonstrate that they are present under the conditions in which they investigate the function of linc00261 (in the ESC model of pancreatic differentiation). The authors could consider, if the smORFs could inhibit ribosome progression or release. Also, the peptides could be unstable and therefore not present endogenously. They must make proper limitations to their conclusions.

Furthermore, the authors claim that mutating all translated ORFs significantly reduce LINC00261 ability to bind ribosomes. They need to perform ribosome association studies with the mutated transcript to make this claim.

Although Figure 4H shows that sORF4 and sORF7 mutations in one of two clones causes a significant reduction in the number of insulin+ cells, the text claims there is no effect on deleting the ORFs. The authors need to resolve this discrepancy. What is the difference between the clones -- if it was KO efficiency then it appears that deletion of these ORFs does have a phenotype.

It is surprising that disruption of the LINC00261 transcript has not phenotype and does not affect FOXA2 gene expression which contradicts previous published studies. At the very least, the authors need to acknowledge this and include some explanation in their Discussion.

Authors should add in a limitations section to list the study limitations such as small number of repeats, need for future experiments relating to single cell analyses and discuss why other reports in human datasets do not see any association in lnc00261 and islet beta cell function.
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Author response

> Essential revisions:
>
> Although this is an interesting study with novel information regarding lncRNAs in islet cell differentiation, the authors make claims throughout the manuscript that are not supported by their data, therefore their conclusions should be limited to what they actually show. The majority of these issues can be corrected by careful editing, but they also somewhat diminish the impact of the study. In addition, the manuscript text should be carefully checked for overstatements. For example, in the first paragraph of the Results section, the authors state that majority of lncRNAs showed dynamic expression patterns. These are not a majority as they represent 37%.

We thank the reviewers for their careful and thorough evaluation of our manuscript. As per their suggestion, we have reassessed all claims and statements made based on our experiments and computational analyses. We have adjusted claims where necessary. With respect to the example given (37% is not the majority), the given Results section reads:

\"While some lncRNAs were constitutively expressed (n = 592; 25.3%), the majority showed dynamic expression patterns, being either strongly enriched in (n = 874; 37.4%), or specific to (n = 871; 37.3%) a single developmental intermediate of pancreatic lineage progression (Figure 1B and Figure 1---source data 1A).\"

With the majority of dynamically expressed lncRNAs, we here referred to the sum of the stage-enriched (i.e. expressed in one or two stages, whilst absent in other stages) and stage-specific (i.e. expressed in a single evaluated stage only) lncRNAs. Together, these two groups of dynamically expressed lncRNAs sum up to a majority of 74.7% (37.4% + 37.3%) of all expressed lncRNAs. We apologize for this ambiguity in our writing and have adjusted this for better clarity in the revised version of the manuscript.

> Primary concern: If the authors wish to claim that the linc00261 function is independent of the smORFs ability to be translated, then they must present data on differentiation capability cells having the simultaneously mutated smORFs, in addition to the linc00261 transcript stability data. In the current version, they have not probed the functional effects of mutating all the smORFs, which could be redundant. However, if they are not able to produce this data, then they will have to change the title and conclusions of the manuscript to reflect what they actually show.

We understand the reviewers\' concern that differentiation of hESCs with all ORFs mutated simultaneously would provide a more definitive answer to the potential combined (or redundant) functions of the translated short ORFs and the microproteins produced from these short ORFs. However, given the size of the LINC00261 locus, introducing all seven point mutations simultaneously (or consecutively) into hESCs to generate ∆ATG mutant LINC00261 hESC lines is technically challenging, if not impossible. Such an experiment comes with significant caveats, such as off-target mutations due to repeated targeting and increased clone-to-clone variability caused by extensive passaging of the hESCs. In addition, due to the requirement for numerous rounds of gene editing, we would not be able to conduct these experiments within a reasonable timeframe for revision, especially now that our laboratory is operating at very limited capacity due to COVID-19.

Based on the experimental evidence we provide, what we can state regarding LINC00261 function is the following: (i) deletion of the entire transcript impairs endocrine cell differentiation and reduces insulin content in endocrine stage cultures, (ii) deletion of the entire transcript has no effect on FOXA2 expression, (iii) mutation of the individual ORFs (one-by-one) does not recapitulate this phenotype, and (iv) upon expression in HEK293T cells, LINC00261 transcripts with or without *all* ORFs mutated at once are equally stable -- the evidence being that there is no difference in LINC00261 abundance in the presence of the transcription inhibitor actinomycin D (Figure 4K). In support of the latter observation, mutation of each of the single ORFs individually also had no effect on LINC00261 abundance in hESC-derived pancreatic cells (Figures 4J and Figure 4---figure supplement 1E). We agree with the reviewers that based on these observations we cannot rule out functional redundancy between the translated ORFs, as upon KO of a single ORF another (non-targeted) ORF or microprotein produced from this ORF may take over part of its functionality.

Our findings allow for the conclusion that the ORFs present in LINC00261 are not translated merely as a means to induce translation-coupled LINC00261 nonsense-mediated decay (NMD), a mechanism that was previously proposed as a potential main reason for lncRNA translation (Tani et al., 2013; Carlevaro-Fita et al., 2016). Taking away all endogenously favored translation initiation sites (at the very minimum) should strongly reduce the ability of the mutated transcript to attract ribosomes, though we show deleting these ORFs had no effect on LINC00261 stability.

As suggested by the reviewers, we have limited our claims to reflect the experimental data provided, and have adjusted the title and conclusions accordingly. We have added discussion on this topic (i.e. the absence of a mutant that has all ORFs mutated) and also refer to this point in the newly introduced \'limitations and future directions\' paragraph.

The new title is: "A human ESC-based screen identifies a role for the translated lncRNA LINC00261 in pancreatic endocrine differentiation"

In the Discussion we state: "It would have been interesting to determine how concurrent mutation of all sORFs in LINC00261 affects pancreatic cell differentiation. However, given the size of the LINC00261 locus and the many sORFs, such an approach comes with technical challenges and significant caveats."

In the limitations and future directions section we state: "LINC00261\'s microproteins and sORFs may have redundant functions which could explain why deletion of individual sORFs produces no apparent phenotype. Thus, despite limited sequence similarity and stark differences in translation rates between the identified translated sORFs in LINC00261, we cannot rule out that different microproteins produced by LINC00261 compensate when one sORF is deleted."

> As for their data on the smORFs (Figure 2), they have shown that the smORF-coding nucleotides bind to the ribosome and generate the classic 3-letter foot-print indicative of translation. They have shown that RNAs corresponding to the smORFs can undergo forced expression with translation into fusion protein using high expression levels in HEK293 cells. However, showing that the smORFs associate with the ribosome or can forcefully be translated, does not demonstrate that they are present under the conditions in which they investigate the function of linc00261 (in the ESC model of pancreatic differentiation). The authors could consider, if the smORFs could inhibit ribosome progression or release. Also, the peptides could be unstable and therefore not present endogenously. They must make proper limitations to their conclusions.

Whether all translated \'non-canonical\' short ORFs (e.g. uORFs and lncRNA ORFs) produce stable proteins has been a subject of debate over the past years. Although we and others have systematically evaluated the protein-coding capacity and functional (regulatory) roles of many of these short ORFs (e.g. van Heesch et al., Cell 2019; Ji et al., Science 2020; Martinez et al., Nat Chem Biol 2019; Prensner et al., 2020), none of these studies provide an ultimate, overall classification that separates regulatory from protein producing ORFs, as these categories are per se not mutually exclusive. Furthermore, many of these ORFs may not be functional at all, but merely byproducts of evolutionary processes that have created the right circumstances for translation. What we do know from the aforementioned studies, is that for about 50-60% of all translated short ORFs microprotein products can generally be detected in vitro and in vivo (as determined by overexpression of lncRNAs with GFP/HA/V5/FLAG tagged ORFs, in vitro translation assays, in vivo shotgun and targeted mass-spectrometry (SRM/PRM), or HLA immunopeptidomics). Despite the challenges that come with the detection of such short protein products, these findings strongly suggest that many microproteins are stable enough to be detected by proteomics in human tissues and cell lines.

To elaborate on this a bit further, and to put our findings into a broader perspective, we investigated (i) how frequently the ORFs we annotate in this study have additionally been found independently in other human studies that used Ribo-seq to annotate short ORFs in lncRNAs, and (ii) for how many of these ORFs protein-level evidence for the produced microprotein could be found -- either from shotgun, targeted, or immunopeptidomic (HLA bound) mass spectrometry approaches. In summary, of the 625 lncRNA ORFs (within 285 lncRNA genes) found to be translated in pancreatic progenitor cells, 410 (66%) are also identified as translated in one or more additional study (but not yet annotated by GENCODE, RefSeq or Ensembl), supporting the quality and reproducibility of the reported Ribo-seq-based ORF annotations. Of these 410 short ORFs, mass spec evidence presented in these additional studies could be found for 165 sORF-encoded microproteins (40% of all theoretically detectable ORFs). These results of course exclude short ORFs translated exclusively in our system (e.g. LINC00261, LHFPL3-AS2 or MIR7-3HG).

Importantly -- and similar to the translation of many uORFs or alternative CDSs in mRNAs (e.g. NMD transcripts) -- the fact that we can find protein products does not exclude a regulatory role for the act of translation of these ORFs. The importance of properly dissecting coding and noncoding roles of a single locus is one of the key points we attempted to make with our manuscript. Guided by gene biotypes, scientists have long and unknowingly ignored the likely dual coding and noncoding functions many genes can have, whether biotyped as lncRNA or protein coding. However, to properly investigate the function of a particular locus, potential coding or noncoding functions must be fully considered. For example, when deleting a protein product, one should ideally leave the RNA sequence and structure largely intact (e.g. by changing only the CDS\'s start codon, but not the nucleotide sequence and structure of the rest of the RNA). We have attempted to do this to the best of our capabilities for LINC00261, by complementing the knockout of the complete gene (RNA and ORFs) with ORF-by-ORF deletions that each leave the expression and sequence of LINC00261 intact.

As suggested by the reviewers, we have expanded the interpretation of our findings by discussing that the act of LINC00261 translation may additionally serve a regulatory purpose and by stressing that we have not evaluated protein-level evidence of LINC00261 microprotein production directly in the hESC differentiation system. We have specifically made note of this in the newly introduced \'limitations and future directions\' paragraph.

In the limitations and future directions section we state: "Second, although we provide evidence that LINC00261 can produce microproteins using Ribo-seq, which is further supported by in vitro translation assays and overexpression of LINC00261 constructs with different in-frame tags, we provide no protein-level evidence for the endogenous production and stability of LINC00261\'s microproteins in this differentiation system or in human pancreas development in vivo."

> Furthermore, the authors claim that mutating all translated ORFs significantly reduce LINC00261 ability to bind ribosomes. They need to perform ribosome association studies with the mutated transcript to make this claim.

We agree that despite mutating multiple ORFs simultaneously, alternative ribosome binding at LINC00261 upon overexpression in HEK293T cells could theoretically occur. However, in the pancreatic progenitor cell Ribo-seq data used to annotate these ORFs, we see very little ribosome binding patterns outside of the newly annotated LINC00261 ORFs. In theory, upon ORF mutation new initiation sites could be selected not utilized under wild type conditions.

Since we provide no direct readout of altered ribosome binding upon ORF mutation, we have softened claims regarding absolute absence of ribosome binding in the revised version of the manuscript, and rephrased these claims to better represent what we have actually tested, i.e. that the absence of the translation of the ORFs endogenously translated in pancreatic progenitors does not influence the stability of LINC00261.

> Although Figure 4H shows that sORF4 and sORF7 mutations in one of two clones causes a significant reduction in the number of insulin+ cells, the text claims there is no effect on deleting the ORFs. The authors need to resolve this discrepancy. What is the difference between the clones -- if it was KO efficiency then it appears that deletion of these ORFs does have a phenotype.

Although we were initially excited to see a possible effect of sORF4 and sORF7 deletion, this effect could only be replicated in one of the two independently generated hESC KO clones. For each of the two clones (Figure 4H) between four and seven independent differentiations were conducted for these measurements, each in comparison to an equal number of wild type clone differentiations carried out side-by-side under the same culture conditions. Furthermore, measurement of insulin content in the same sORF4 and sORF7 KO endocrine cell stage cultures revealed no significant difference (Figure 4I), which contrasts our findings in LINC00261 KO clones (Figure 4C). The lack of a reproducible result between both clones and the lack of an effect on insulin production was sufficient reason for us to classify the observation as non-consistent, and we have now clarified this in the Results section of the revised manuscript.

All clones contain homozygous mutations for which individual colonies were handpicked and subsequently genotyped. Since for each clone, the ORF KO was validated by genotyping (through Sanger sequencing), seeing a phenotype in only a single clone is more likely to be the result of an unknown off target effect, rather than it being attributable to the (efficiency of the) ORF deletion itself.

In the Results we now state: "We observed no difference between sORF loss-of-function and control hESC lines for most of these endpoints (Figure 4H, I and Figure 4---figure supplement 1E), although we noticed that the number of insulin^+^ cells, but not the amount of insulin produced, was reduced in one of the two sORF4 and sORF7 KO clones."

> It is surprising that disruption of the LINC00261 transcript has not phenotype and does not affect FOXA2 gene expression which contradicts previous published studies. At the very least, the authors need to acknowledge this and include some explanation in their Discussion.

We were also surprised by this finding and the fact that LINC00261, as well as several other lncRNAs we deleted, did not affect the expression of neighboring (sense) protein-coding genes. However, as summarized below, the evidence that we collected is rigorous, and we are certain that our results are sound and correct, even though they contrast a number of previous studies that have reported a cis-regulatory relationship between LINC00261 and FOXA2 (e.g. Jiang et al., 2015; Swarr et al., 2019; Amaral et al., 2018). Differences in cell context and experimental approach could account for the differences, as detailed below.

We examined FOXA2 mRNA expression in LINC000261 knockout cells (LINC00261^-/-^ cells) at two stages of in vitro differentiation: (i) in definitive endoderm, which is the same cell context in which Jiang et al., 2015 observed FOXA2 regulation, and (ii) in pancreatic progenitors. We used qRT-PCR and RNA-seq as independent methods and both show no evidence for regulation of FOXA2 by LINC00261 (Figures 3D, Figure 3---figure supplement 1C, 4F, Figure 4---figure supplement 1C). In addition, we show that there is no difference in FOXA2 protein expression between control and LINC00261^-/-^ cells by immunofluorescence staining in definitive endoderm (Figure 3F). Thus, we provide clear and rigorous evidence in two distinct cellular contexts that LINC00261 does not regulate FOXA2 during human endoderm development.

One important difference between our study and the study by Jiang et al. is that we used a CRISPR-Cas9-mediated deletion strategy while Jiang et al. employed shRNAs to knockdown LINC00261 in human definitive endoderm. It is possible that shRNA-mediated knockdown produces different effects. Furthermore, compared to our differentiation protocol, the differentiation strategy applied by Jiang et al. to generate definitive endoderm was less efficient in inducing definitive endoderm. It is possible that cells generated with the Jiang et al. protocol may be inherently less stable in their cell fate choice, which could influence effects of LINC00261 loss-of-function on gene regulation. Amaral et al. studied LINC00261 in human cancer cell lines and similar to Jiang et al. used siRNAs rather than deletion. Swarr et al. studied LINC00261 by knockout in mice but not in human cells. While LINC00261 is positionally conserved between mouse and human, the sequence conservation is poor. Species differences might explain the difference between our findings in human cells and Swarr's findings in mouse lung.

As suggested by the reviewers, we have included a detailed discussion of the discrepancies between our results and previous studies in the Discussion section under the heading "Limited cis-regulatory consequences of lncRNA deletion" of our revised manuscript.

> Authors should add in a limitations section to list the study limitations such as small number of repeats, need for future experiments relating to single cell analyses and discuss why other reports in human datasets do not see any association in lnc00261 and islet beta cell function.

To address the concerns, we have expanded the Discussion and also added a limitations and future directions section to the Discussion, where we highlight the following aspects:

i\) differences exist between differentiation protocols for the generation of definitive endoderm and endocrine cells. How much these recapitulate the in vivo situation is not known, but culture conditions could impact gene regulation and might explain the discrepancies between studies using different protocols. For example, the effect of LINC00261 knockout or knockdown on FOXA2 expression could be protocol dependent. We make clear that we use a stem-cell based in vitro differentiation system, and that we cannot make immediate inferences on conditions that govern human in vivo development.

ii\) ORFs or the produced microproteins may have redundant functions, which we did not assess in our differentiation system (as we only target individual ORFs on a one-by-one basis).

iii\) For the cytoplasmic and nuclear fractionation experiments, we have only used an n of two. We have adjusted the visualization of these data to clarify this and have mentioned this as a limitation to the interpretation of these data. We have been fully transparent on the precise number of replicates used for all experiments, throughout the figure legends, Results, and Materials and methods sections. We note that our findings on the role of LINC00261 in endocrine cell differentiation are supported by analysis of a total of *24* independent in vitro differentiations across four independently targeted hESC clones. Therefore, these findings have no limitations regarding replicate numbers.
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